Spectrum Pharmaceuticals (SPPI) 10-K12 Mar 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'SPPI	'	'
Entity Registrant Name	'SPECTRUM PHARMACEUTICALS INC	'	'
Entity Central Index Key	'0000831547	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	65,287,782	'
Entity Public Float	'	'	$449,722,900

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and equivalents	$156,306	$139,698
Marketable securities	3,471	3,310
Accounts receivable, net of allowance for doubtful accounts of $206 and $228, respectively	49,483	92,169
Other receivables	7,539	'
Inventories	13,519	14,478
Prepaid expenses and other current assets	3,213	2,745
Deferred tax assets	1,659	12,473
Total current assets	235,190	264,873
Property and equipment, net	1,535	2,548
Intangible assets, net	231,352	200,234
Goodwill	18,501	7,279
Deferred tax assets	'	23,276
Other assets	12,577	6,745
Total assets	499,155	504,955
Current liabilities:	'	'
Accounts payable and other accrued liabilities	79,837	105,252
Accrued payroll and related expenses	6,872	4,835
Deferred revenue	156	12,300
Drug development liability	3,119	856
Total current liabilities	89,984	123,243
Drug development liability, less current portion	14,623	11,377
Deferred payment contingency	'	2,287
Acquisition-related contingent obligations	8,329	'
Deferred tax liability	7,168	'
Other long-term liabilities	5,965	4,367
Revolving line of credit	'	75,000
Convertible senior notes	91,480	'
Total liabilities	217,549	216,274
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock	'	'
Common stock, $0.001 par value; 175,000,000 shares authorized; 64,104,173 and 60,026,675 issued and outstanding at December 31, 2013 and 2012, respectively	64	60
Additional paid-in capital	518,144	463,710
Accumulated other comprehensive income	894	273
Accumulated deficit	-237,619	-175,485
Total stockholders' equity	281,606	288,681
Total liabilities and stockholders' equity	499,155	504,955
Series B Junior Participating Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock	'	'
Series E Convertible Voting Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock	$123	$123

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Allowance for doubtful accounts receivable	$206	$228
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	175,000,000	175,000,000
Common stock, shares issued	64,104,173	60,026,675
Common stock, shares outstanding	64,104,173	60,026,675
Series B Junior Participating Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series E Convertible Voting Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, stated value	$10,000	$10,000
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	20	20
Preferred stock, shares outstanding	20	20
Convertible preferred shares	40,000	40,000
Preferred stock, liquidation value	$240	$240

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Product sales, net	$143,475	$254,992	$180,663
License fees and service revenue	12,379	12,715	12,300
Total revenues	155,854	267,707	192,963
Operating costs and expenses:	'	'	'
Cost of product sales (excludes amortization of purchased intangible assets)	28,580	46,633	33,838
Selling, general and administrative	99,315	89,922	72,197
Research and development	46,670	41,560	26,662
Amortization and impairment of intangible assets	20,074	8,818	3,720
Total costs and operating expenses	194,639	186,933	136,417
(Loss) income from operations	-38,785	80,774	56,546
Other income (expense):	'	'	'
Interest expense, net	-2,192	-485	297
Change in fair value of contingent consideration related to acquisition	2,871	'	'
Change in fair value of common stock warrant liability	-356	'	-3,488
Other income (expense), net	1,470	-359	280
Total other income (expense)	2,149	-844	-2,911
(Loss) income before income taxes	-36,636	79,930	53,635
(Provision) benefit for income taxes	-25,498	14,271	-3,704
Net (loss) income	($62,134)	$94,201	$49,931
Net (loss) income per share:	'	'	'
Basic	($1.02)	$1.61	$0.94
Diluted	($1.02)	$1.46	$0.86
Weighted average shares outstanding:	'	'	'
Basic	60,729,128	58,588,916	53,272,767
Diluted	60,729,128	64,637,256	57,959,714

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Partners Capital [Abstract]	'	'	'
Net (loss) income	($62,134)	$94,201	$49,931
Other comprehensive (loss) income, net of tax:	'	'	'
Unrealized gain (loss) on available-for-sale securities	1,110	797	-135
Income tax on unrealized gain on available-for-sale securities	-420	-213	'
Foreign currency translation adjustments	-69	-84	'
Other comprehensive income (loss), net	621	500	-135
Total comprehensive (loss) income	($61,513)	$94,701	$49,796

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total Stockholders Equity [Member]
In Thousands, except Share data	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total Stockholders Equity [Member]
Beginning Balance at Dec. 31, 2010	'	$160	$51	$384,757	($92)	($307,635)	'	$77,241
Beginning Balance, Shares at Dec. 31, 2010	'	26	51,459,284	'	'	'	'	'
Net income (loss)	49,931	'	'	'	'	49,931	'	49,931
Other comprehensive Income (loss), net	49,796	'	'	'	-135	'	'	-135
Conversion of Series E preferred stock to common stock	-37	-37	'	37	'	'	'	'
Conversion of Series E preferred stock to common stock, Shares	'	-6	12,000	'	'	'	'	'
Issuance of common stock to 401(k) plan	'	'	'	593	'	'	'	593
Issuance of common stock to 401(k) plan, Shares	'	'	65,889	'	'	'	'	'
Issuance of common stock for ESPP	'	'	'	655	'	'	'	655
Issuance of common stock for ESPP, Shares	'	'	100,386	'	'	'	'	'
Adjustments resulting from change in value of warrants recognized in equity	'	'	'	7,392	'	'	'	7,392
Issuance of common stock upon exercise of stock options	'	'	1	5,136	'	'	'	5,137
Issuance of common stock upon exercise of stock options, Shares	1,126,257	'	1,126,257	'	'	'	'	'
Issuance of common stock upon exercise of warrants	'	'	4	24,804	'	'	'	24,808
Issuance of common stock upon exercise of warrants, Shares	'	'	3,747,312	'	'	'	'	'
Share-based compensation expense and common stock issued (net of forfeitures)	'	'	1	21,643	'	'	'	21,644
Share-based compensation expense and common stock issued (net of forfeitures), Shares	'	'	998,711	'	'	'	'	'
Purchase of treasury stock	'	'	'	'	'	'	-2,926	-2,926
Purchase of treasury stock, Shares	'	'	'	'	'	'	363,055	'
Issuance of restricted stock for management incentive plan, net of shares repurchased/retired for employee tax withholding	'	'	1	-4,033	'	'	'	-4,032
Issuance of restricted stock for management incentive plan, net of shares repurchased/retired for employee tax withholding, Shares	'	'	426,562	'	'	'	'	'
Fair value of common stock issued to Targent for milestone	'	'	1	11,777	'	'	'	11,778
Fair value of common stock issued, Shares	'	'	1,311,082	'	'	'	'	'
Ending Balance at Dec. 31, 2011	'	123	59	452,761	-227	-257,704	-2,926	192,086
Ending Balance, Shares at Dec. 31, 2011	'	20	59,247,483	'	'	'	363,055	'
Net income (loss)	94,201	'	'	'	'	94,201	'	94,201
Other comprehensive Income (loss), net	94,701	'	'	'	500	'	'	500
Issuance of common stock to 401(k) plan	'	'	'	691	'	'	'	691
Issuance of common stock to 401(k) plan, Shares	'	'	56,254	'	'	'	'	'
Issuance of common stock for ESPP	'	'	'	606	'	'	'	606
Issuance of common stock for ESPP, Shares	'	'	54,521	'	'	'	'	'
Issuance of common stock upon exercise of stock options	'	'	2	5,815	'	'	'	5,817
Issuance of common stock upon exercise of stock options, Shares	1,287,430	'	1,287,430	'	'	'	'	'
Issuance of common stock upon exercise of warrants	'	'	'	89	'	'	'	89
Issuance of common stock upon exercise of warrants, Shares	'	'	50,000	'	'	'	'	'
Share-based compensation expense and common stock issued (net of forfeitures)	'	'	'	14,193	'	'	'	14,193
Share-based compensation expense and common stock issued (net of forfeitures), Shares	'	'	554,239	'	'	'	'	'
Repurchase of shares to satisfy employee tax withholding	'	'	'	-1,434	'	'	'	-1,434
Repurchase of shares to satisfy employee tax withholding, Shares	'	'	-120,197	'	'	'	'	'
Dividends paid	'	'	'	-9,011	'	'	'	-9,011
Purchase of treasury stock	'	'	'	'	'	'	-9,057	-9,057
Purchase of treasury stock, Shares	'	'	'	'	'	'	740,000	'
Retirement of treasury stock	-11,983	'	-1	'	'	-11,982	11,983	'
Retirement of treasury stock, Shares	'	'	-1,103,055	'	'	'	-1,103,055	'
Ending Balance at Dec. 31, 2012	'	123	60	463,710	273	-175,485	'	288,681
Ending Balance, Shares at Dec. 31, 2012	60,026,675	20	60,026,675	'	'	'	'	'
Net income (loss)	-62,134	'	'	'	'	-62,134	'	-62,134
Other comprehensive Income (loss), net	-61,513	'	'	'	621	'	'	621
Issuance of common stock to 401(k) plan	'	'	'	860	'	'	'	860
Issuance of common stock to 401(k) plan, Shares	'	'	99,359	'	'	'	'	'
Issuance of common stock for ESPP	'	'	'	495	'	'	'	495
Issuance of common stock for ESPP, Shares	'	'	74,925	'	'	'	'	'
Issuance of common stock upon exercise of stock options	'	'	1	3,576	'	'	'	3,577
Issuance of common stock upon exercise of stock options, Shares	825,884	'	825,884	'	'	'	'	'
Share-based compensation expense and common stock issued (net of forfeitures)	'	'	'	11,913	'	'	'	11,913
Share-based compensation expense and common stock issued (net of forfeitures), Shares	'	'	471,875	'	'	'	'	'
Repurchase of shares to satisfy employee tax withholding	'	'	'	-1,509	'	'	'	-1,509
Repurchase of shares to satisfy employee tax withholding, Shares	'	'	-159,545	'	'	'	'	'
Purchase of treasury stock	'	'	'	'	'	'	-1,651	-1,651
Purchase of treasury stock, Shares	'	'	'	'	'	'	235,000	'
Retirement of treasury stock	-1,652	'	'	-1,651	'	'	1,651	'
Retirement of treasury stock, Shares	'	'	-235,000	'	'	'	-235,000	'
Issuance of common stock for Talon acquisition	'	'	3	26,307	'	'	'	26,310
Issuance of common stock for Talon acquisition, Shares	'	'	3,000,000	'	'	'	'	'
Issuance of 2018 Convertible Notes	'	'	'	14,443	'	'	'	14,443
Ending Balance at Dec. 31, 2013	'	$123	$64	$518,144	$894	($237,619)	'	$281,606
Ending Balance, Shares at Dec. 31, 2013	64,104,173	20	64,104,173	'	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Flows From Operating Activities:	'	'	'
Net (loss) income	($62,134)	$94,201	$49,931
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:	'	'	'
Amortization of deferred service revenue	-12,400	-12,300	-12,300
Depreciation and amortization	22,096	12,243	5,650
Stock-based compensation	12,423	14,884	22,237
Change in fair value of common stock warrants issued to non-employees	356	'	3,488
Accretion of debt discount to interest expense on 2018 Convertible Notes	43	'	'
Amortization of deferred financing costs to interest expense on 2018 Convertible Notes	101	'	'
Bad debt expense (recovery)	127	-128	245
Loss on disposal of fixed assets	'	132	38
Non-cash foreign currency exchange loss	1,222	107	'
Impairment of FOLOTYN distribution rights	1,023	'	'
Change in fair value of contingent consideration related to acquisition	-2,871	20	'
Change in fair value of Allos deferred development costs and deferred payment contingency	-2,869	'	'
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	42,559	-33,504	-30,897
Inventories	1,570	3,530	-6,528
Prepaid expenses and other current assets	-359	9,483	-7,115
Deferred tax assets	33,252	-34,605	'
Other assets	-8,989	'	'
Accounts payable and other accrued obligations	-23,897	24,038	15,711
Accrued payroll and related expenses	425	-9,726	-1,525
Drug development liability	-5,917	2,376	3,519
Other long-term liabilities	2,153	1,208	834
Net cash (used in) provided by operating activities	-2,086	71,959	43,288
Cash Flows From Investing Activities:	'	'	'
Sales and maturities of marketable securities	'	72,463	18,255
Purchases of marketable securities	'	-26,430	-17,027
Purchases of property and equipment	-161	-312	-475
Purchases of available-for-sale securities	'	-1,712	-164
Proceeds from sale of available-for-sale securities	'	'	157
Acquisition of Allos, net of cash acquired	'	-133,264	'
Net cash (used in) provided by investing activities	-14,330	-114,690	746
Cash Flows From Financing Activities:	'	'	'
Proceeds from Mundipharma for FOLOTYN development	7,000	'	'
Proceeds from exercise of stock options	3,576	5,817	5,137
Proceeds from exercise of common stock warrants	'	89	24,808
Proceeds from sale of common stock under employee stock purchase plan	495	606	655
Payments to acquire treasury stock	-1,651	-9,057	-2,926
Repurchase of restricted stock to satisfy employee tax withholdings at vesting	-1,509	-1,434	-4,032
Payment of stock dividend	'	-9,011	'
Repayment of capital leases	'	-9	-31
Proceeds from revolving line of credit	100,000	125,000	'
Repayment of revolving line of credit	-175,000	-50,000	'
Proceeds from 2018 convertible Notes	120,000	'	'
Deferred financing costs	-4,573	'	'
Proceeds from sale of common stock warrants related to 2018 Convertible Notes issuance	12,612	'	'
Payment of debt issuance costs	'	-976	'
Purchase of common stock call options related to 2018 Convertible Notes issuance	-25,692	'	'
Net cash provided by financing activities	35,258	61,025	23,611
Effect of exchange rates on cash and equivalents	-2,235	202	'
Net increase (decrease) in cash and equivalents	16,608	18,496	67,645
Cash and equivalents - beginning of year	139,698	121,202	53,557
Cash and equivalents - end of year	156,306	139,698	121,202
Supplemental Disclosure of Cash Flow Information:	'	'	'
Cash paid for income taxes	'	17,157	2,042
Cash paid for interest	1,200	495	14
Retirement of treasury shares	1,652	11,983	'
Inventory liability assumed in acquisitions	'	580	'
Inventory included in accounts payable	'	5,000	'
Conversion of preferred stock to common stock	'	'	37
ZEVALIN Rights [Member]	'	'	'
Cash Flows From Investing Activities:	'	'	'
Acquisition of Allos, net of cash acquired	'	-25,435	'
C-E MELPHALAN rights [Member]	'	'	'
Cash Flows From Investing Activities:	'	'	'
Acquisition of Allos, net of cash acquired	-3,000	'	'
Talon [Member]	'	'	'
Cash Flows From Investing Activities:	'	'	'
Acquisition of Allos, net of cash acquired	-11,169	'	'
Supplemental Disclosure of Cash Flow Information:	'	'	'
Common stock issued for acquisition	26,310	'	'
Targent [Member]	'	'	'
Supplemental Disclosure of Cash Flow Information:	'	'	'
Common stock issued for acquisition	'	'	$11,778

Description_of_Business_Basis_

Description of Business, Basis of Presentation, and Operating Segment	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Description of Business, Basis of Presentation, and Operating Segment	'
	1	DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT
	(a) Description of Business
	Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (“Spectrum”, the “Company”, “we”, “our”, or “us”), is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products.
	We currently market four drugs:

		•	FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

		•	ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma;

		•	FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and

		•	MARQIBO injection for patients in the U.S. with Philadelphia chromosome–negative acute lymphoblastic leukemia.
	We also have a pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research, regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.
	(b) Basis of Presentation
	Principles of Consolidation
	The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.
	On April 1, 2012, we acquired the licensing rights outside of the U.S. to market ZEVALIN (the “ZEVALIN Rights”); on September 5, 2012, we acquired Allos Therapeutics, Inc. (“Allos”); and on July 17, 2013, we acquired Talon Therapeutics, Inc. (“Talon”). Our accompanying Consolidated Financial Statements include the assets acquired and liabilities assumed in connection with these acquisitions, in addition to the operating results and cash flows, beginning with the corresponding acquisition date for each acquisition.
	Variable Interest Entity
	We own fifty-percent of Spectrum Pharma Canada (a “variable interest entity,” as defined under applicable GAAP), which was organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this entity. We are obligated to fund all costs of this entity and have the sole rights to any revenue derived from its operations. Since we carry the full risks and rewards of this entity, we meet the applicable GAAP criteria as its “primary beneficiary”. As the primary beneficiary of this variable interest entity, Spectrum Pharma Canada’s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.
	(c) Operating Segment
	We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December 31, 2013, 2012, and 2011, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our long-lived assets are located in the U.S.

Summary_of_Significant_Account

Summary of Significant Accounting Policies and Use of Estimates	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies and Use of Estimates	'
	2	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES
	The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, our management evaluates its estimates, including those related to (i) revenue adjustments; (ii) the collectability of customer accounts; (iii) whether the cost of inventories can be recovered; (iv) the value of goodwill and intangible assets; (v) the realization of tax assets and estimates of tax liabilities; (vi) the likelihood of payment and value of contingent liabilities; (vii) the fair value of investments; (viii) assumptions used in reporting stock-based compensation; and (ix) the potential outcome of litigation.
	Such estimates are based on our management’s judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may materially differ from management’s estimates. In our judgment, the accounting policies, estimates, and assumptions described below have the potential to significantly impact our preparation of the accompanying Consolidated Financial Statements:
	(i) Revenue Recognition
	(a) Product Sales: We sell our products to wholesalers and distributors. Our wholesalers and distributors purchase our products and sell the products directly to end-users, such as clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized upon shipment of product when title and risk of loss have transferred to our customer, and the following additional criteria are met:

		-1	appropriate evidence of a binding arrangement exists with our customer;

		-2	price is substantially fixed and determinable;

		-3	collection from our customer is reasonably assured;

		-4	our customer’s obligation to pay us is not contingent on resale of the product;

		-5	we do not have significant obligations for future performance to directly bring about the resale of our product; and

		-6	we have a reasonable basis to estimate returns.
	Our gross revenue is reduced by our gross-to-net (“GTN”) estimates, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.
	Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:
	Product Returns Allowances: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.
	Government Chargebacks: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.
	Discounts: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.
	Rebates: Rebates are estimated based on the customer’s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.

	Medicaid Rebates: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management’s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.
	Distribution and Data Fees: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.
	(b) License Fees: We recognize license fees based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum license fee in which revenue is recognized in that period.
	(c) Service Revenue: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.
	(ii) Cash and Equivalents
	Cash and equivalents consist of highly liquid investments with original maturities of three months or less from the original purchase date.
	(iii) Marketable Securities
	Marketable securities are equity securities. These are classified as available-for-sale, with any unrealized change in value reflected in “unrealized gain (loss) on securities” on the accompanying Consolidated Statements of Comprehensive Income (Loss).
	(iv) Accounts Receivable
	Accounts receivable are recorded at the invoiced amount, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.
	(v) Inventories
	We value inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory (i.e., net realizable value). Cost is determined on the first-in, first-out method (FIFO). We regularly review inventory quantities in process and on hand, and when appropriate, record a provision for obsolete and excess inventory to reduce it to its net realizable value.
	(vi) Property and Equipment
	Property and equipment are stated at cost and depreciated on a straight-line basis over its estimated useful lives. In the case of leasehold improvements, depreciation is over the shorter of the estimated useful life or remaining term of the lease. We evaluate the recoverability of long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.

	(vii) Goodwill and Intangible Assets
	Goodwill represents the excess of acquisition cost over the fair value of the net assets of the acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually unless there are interim impairment indicators. We perform our annual evaluation as of October 1 each year.
	We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:

		(a)	a significant decrease in the market value of an asset;

		(b)	a significant adverse change in the extent or manner in which an asset is used; or

		(c)	an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.
	(viii) Stock-Based Compensation
	We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.
	We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.
	(ix) Foreign Currency Translation
	We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using rates of exchange in effect during the period. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of comprehensive income (loss).
	We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any period presented.
	(x) Comprehensive Income (Loss)
	Comprehensive income (loss) is calculated in accordance with authoritative guidance which requires the disclosure of all components of comprehensive income, including net income (loss) and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources.
	(xi) Basic and Diluted Net (Loss) Income per Share
	We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.
	(xii) Income Taxes
	Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.
	We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance of our deferred tax assets would increase net income in the period such determination was made. In the event that we were assessed interest and/or penalties from taxing authorities, such amounts would be included in “income tax expense” within the Consolidated Statements of Operations and Comprehensive Income (Loss) in the period the notice was received.
	(xiii) Research and Development Costs
	Research and development costs are expensed as incurred.
(xiv) Fair Value Measurements
We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
“Cash and equivalents” within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. “Marketable securities” consist of publicly-traded equity instruments that are valued utilizing Level 1 inputs.
The fair value of our “drug development liability” and our “deferred payment contingency” within our accompanying Consolidated Balance Sheets was valued using a model commonly referred to as the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i) internal estimates of research and development personnel costs needed to perform the research and development services, (ii) estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.
“Acquisition-related contingent obligations” within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with various business combinations. See Note 10(a) for a discussion of CVRs granted as part of our acquisition of Talon, and Note 10(b) for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.

Balance_Sheet_Account_Detail

Balance Sheet Account Detail	12 Months Ended
Balance Sheet Account Detail	Dec. 31, 2013
Text Block [Abstract]	'
Balance Sheet Account Detail	'
	3	BALANCE SHEET ACCOUNT DETAIL
	(a) Cash and Equivalents and Marketable Securities
	As of December 31, 2013, we held substantially all of our cash and equivalents, and marketable securities at major financial institutions.
	Our investment policy requires that investments in marketable securities be in only highly-rated instruments, which are primarily U.S. treasury bills or U.S. treasury-backed securities, with limitations on investing in securities of any single issuer. We maintain cash balances in excess of federally insured limits with reputable financial institutions. To a limited degree, the Federal Deposit Insurance Corporation (FDIC) and other third parties insure these investments. However, these investments are not insured against the possibility of a complete loss of earnings or principal and are inherently subject to the credit risk related to the continued credit worthiness of the underlying issuer and general credit market risks. We manage such risks on our portfolio by investing in highly liquid, highly rated instruments and do not invest in long-term maturity instruments.

	Cash and equivalents and marketable securities, including long term bank certificates of deposits, and investments totaled $159.8 million and $143.0 million as of December 31, 2013 and 2012, respectively. The carrying amount of our money market funds and bank certificate of deposits (“Bank CDs”) approximates its fair value (utilizing Level 2 inputs – see Note 2(x)) because of our ability to immediately convert these instruments into cash with minimal change in value.
	The following is a summary of our cash and equivalents and marketable securities:


			Cost				Gross				Gross			Estimated			Cash and			Marketable Securities
							Unrealized				Unrealized			fair			equivalents			Marketable Securities
							Gains				Losses			Value						Current			Long
																				Current			Term
	December 31, 2013
	Bank deposits		$	55,911			$	—			$	—		$	55,911		$	55,911		$	—		$	—
	Money market funds			100,395											100,395			100,395
	Bank CDs			410				—				—			410			—			410			—
	Mutual funds			3,061				—				—			3,061			—			3,061			—

	Total cash and equivalents and marketable securities		$	159,777			$	—			$	—		$	159,777		$	156,306		$	3,471		$	—

	December 31, 2012
	Bank deposits		$	128,000			$	—			$	—		$	128,000		$	128,000		$	—		$	—
	Money market funds			11,698											11,698			11,698
	Bank CDs			987				—				—			987			—			987			—
	Mutual funds			2,323				—				—			2,323			—			2,323			—

	Total cash and equivalents and marketable securities		$	143,008			$	—			$	—		$	143,008		$	139,698		$	3,310		$	—

	As of December 31, 2013, none of these securities had been in a continuous unrealized loss position longer than one year.
	(b) Property and Equipment
	Property and equipment consist of the following:


			December 31,
			2013				2012
	Computers and software		$	5,154			$	4,540
	Lab and media equipment			1,063				886
	Office furniture and equipment			1,575				1,492
	Leasehold improvements			2,813				2,799
	Assets held under capital lease obligations			—				146

	Property and equipment, at cost			10,605				9,863
	(Less): accumulated depreciation and amortization			(9,070	)			(7,315	)

	Property and equipment, net		$	1,535			$	2,548

	Depreciation and amortization expense for property and equipment (including leasehold improvements) for the years ended December 31, 2013, 2012, and 2011 was $1.2 million, $1.2 million, and $0.9 million, respectively.

	(c) Inventories
	Inventories, net consist of the following:


			December 31,
			2013				2012
	Raw materials		$	1,794			$	887
	Work in process			3,312				7,302
	Finished goods			8,413				6,289

	Inventories		$	13,519			$	14,478

	(d) Intangible Assets and Goodwill
	Intangible assets consist of the following:


						December 31, 2013
		Historical				Accumulated				Foreign			Impairment			Net Amount			Full			Remaining
		Cost				Amortization				Currency									Amortization			Amortization
										Translation									Period (years)			Period (years)
MARQIBO IPR&D		$	17,600			$	—			$	—		$	—		$	17,600			n/a			n/a
MELPHALAN IPR&D			7,700				—				—			—			7,700			n/a			n/a
MARQIBO developed technology			26,900				(1,107	)			—			—			25,793			11			11
ZEVALIN marketing rights – U.S.			41,900				(23,455	)			—			—			18,445			10			5
ZEVALIN marketing rights – Ex-U.S.			23,490				(5,343	)			682			—			18,829			8			6
FUSILEV developed technology			16,778				(4,821	)			—			—			11,957			11			8
FOLOTYN distribution rights*			27,900				(3,662	)			—			(1,023	)		23,215			10			9
FOLOTYN developed technology			118,400				(10,587	)			—			—			107,813			13			12

Total intangible assets		$	280,668			$	(48,975	)		$	682		$	(1,023	)	$	231,352


*	On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., the FOLOTYN distribution rights). We determined that an impairment of the FOLOTYN distribution rights of $1.0 million resulted from the amendment and is recorded in the “amortization and impairment of intangible assets” in the accompanying Consolidated Statement of Operations for the year ended December 31, 2013.


		December 31, 2012
		Historical				Accumulated				Foreign			Net
		Cost				Amortization				Currency			Amount
										Translation
ZEVALIN marketing rights – U.S.		$	41,900			$	(19,735	)		$	—		$	22,165
ZEVALIN marketing rights – Ex-U.S.			23,490				(2,192	)			(355	)		20,943
FUSILEV developed technology			16,778				(2,980	)			—			13,798
FOLOTYN distribution rights			27,900				(895	)			—			27,005
FOLOTYN developed technology			118,400				(2,077	)			—			116,323

Total intangible assets		$	228,468			$	(27,879	)		$	(355	)	$	200,234


Intangible asset amortization expense recognized in 2013, and 2012, and 2011 was $21.2 million, $8.8 million, and $4.7 million, respectively. Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:


Years Ending December 31
2014		$	22,468
2015			22,468
2016			22,468
2017			22,468
2018			22,313
2019 and thereafter			93,867

		$	206,052

Goodwill is comprised of the following (by source):


		December 31,				December 31,
		2013				2012
Acquisition of Talon		$	10,526				—
Acquisition of ZEVALIN Rights			2,525			$	2,525
Acquisition of Allos			5,346				4,791
Foreign exchange translation effects			104				(37	)

		$	18,501			$	7,279

(e) Other assets
Other assets are comprised of the following:


		December 31,				December 31,
		2013				2012
Investments in equity securities		$	3,593			$	2,476
Deposits			190				304
Debt issuance cost			3,432				814
Life insurance cash surrender value			5,361				2,881

		$	12,576			$	6,475

(f) Accounts payable and other accrued obligations
Accounts payable and other accrued obligations are comprised of the following:


		December 31,
		2013				2012
Trade payables		$	12,796			$	30,814
Accrued rebates			28,893				11,023
Accrued product royalty			9,498				12,275
Allowance for returns			2,900				5,056
Accrued data and distribution fees			2,430				8,449
Accrued GPO administrative fees			2,327				2,650
Inventory management fee			616				3,050
Accrued income taxes			3				2,522
Allowance for chargebacks			5,074				15,153
Accrued drug development costs			6,433				11,441
Other accrued obligations			8,867				2,819

		$	79,837			$	105,252


Amounts presented within “accounts payable and other accrued obligations” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:


Description		Rebates and				Data and				Prompt			Returns
		Chargebacks				Distribution,				Pay
						GPO Fees, and				Discount
						Inventory
						Management
						Fees

Balance as of December 31, 2011		$	9,064			$	9,808			$	992		$	4,000
Allos accruals assumed			2,371				182				—			941
Add: provisions (recovery)			91,059				32,793				4,814			159
Less: credits or actual allowances			(76,318	)			(28,634	)			(4,355	)		(44	)

Balance as of December 31, 2012			26,176				14,149				1,451			5,056
Add: provisions (recovery)			63,609				19,067				183			(2,034	)
Less: credits or actual allowances			(55,818	)			(27,843	)			(1,317	)		(122	)

Balance as of December 31, 2013		$	33,967			$	5,373			$	317		$	2,900

(g) Other long-term liabilities
Other long-term liabilities are comprised of the following:


		December 31,
		2013				2012
Accrued executive deferred compensation		$	3,949			$	2,366
Deferred rent (non-current portion)			366				571
Business acquisition liability			298				298
Other tax liabilities			1,352				1,132

		$	5,965			$	4,367

Grossto_Net_Product_Sales

Gross-to Net Product Sales	12 Months Ended
Gross-to Net Product Sales	Dec. 31, 2013
Text Block [Abstract]	'
Gross-to Net Product Sales	'
	4	GROSS-TO-NET PRODUCT SALES
	The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:


			2013			2012			2011
	Gross product sales		$	224,301		$	383,817		$	220,670
	Rebates and government chargebacks			(63,610	)		(91,059	)		(22,190	)
	Distribution and data fees and group purchasing organizations fees			(19,067	)		(32,793	)		(11,637	)
	Prompt pay discounts			(183	)		(4,814	)		(4,086	)
	Product returns allowance			2,034			(159	)		(2,094	)

	Product sales, net		$	143,475		$	254,992		$	180,663

Product_Sales_Net_by_Geographi

Product Sales, Net by Geographic Region and Product Line	12 Months Ended
Product Sales, Net by Geographic Region and Product Line	Dec. 31, 2013
Text Block [Abstract]	'
Product Sales, Net by Geographic Region and Product Line	'
	5	PRODUCT SALES, NET BY GEOGRAPHIC REGION AND PRODUCT LINE
	The below table presents product sales, net by geography for the years ended December 31, 2013, 2012, and 2011:


			Year Ended December 31,
			2013				2012				2011
	United States		$	133,462	93	%	$	245,697	96.4	%	$	180,663	—	%

	International:
	Europe			3,953	2.8	%		3,113	1.2	%		—	—	%
	Asia Pacific			6,060	4.2	%		6,182	2.4	%		—	—	%

	Total International			10,013	7	%		9,295	3.6	%		—	—	%

	Product sales, net		$	143,475	100	%	$	254,992	100	%	$	180,663	100	%


	The below table presents product sales, net by product line for the years ended December 31, 2013, 2012, and 2011:


			Year Ended December 31,
			2013				2012				2011
	FUSILEV		$	68,397	47.7	%	$	204,253	80.1	%	$	153,110	84.7	%
	FOLOTYN			44,370	30.9	%		20,412	8	%		—	—	%
	ZEVALIN			29,393	20.5	%		30,327	11.9	%		27,553
	MARQIBO			1,315	0.9	%		—	—	%		—	—	%

	Product sales, net		$	143,475	100	%	$	254,992	100	%	$	180,663	15.3	%

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	6	STOCK-BASED COMPENSATION
	2009 Stock Incentive Plan
	We have one active stockholder-approved stock-based compensation plan, the 2009 Incentive Award Plan (the “2009 Plan”), which replaced our former stockholder-approved plans. We may grant incentive stock options, non-qualified options, restricted stock awards, and stock appreciation rights under the 2009 Plan.
	The maximum number of our common stock available for issuance under the 2009 Plan is 10.0 million shares. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the 2009 Plan increases by the greater of (i) 2.5 million shares or (ii) a number of shares such that the total number of shares of common stock available for issuance under the 2009 Plan shall equal 30% of the then number of shares of common stock issued and outstanding. As of December 31, 2013, 5.7 million shares were available for grant. It is our policy that before stock is issued through the exercise of stock options, we must first receive all required cash payment for such shares (whether through an upfront cash exercise or net-settlement exercise).
	Stock-based awards are governed by agreements between us and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2009 Plan at an exercise price of not less than 100% of the closing fair market value of our common stock on the respective date of grant. The grant date is generally the date the award is approved by the Compensation Committee of the Board of Directors, though for aggregate awards of 50,000 or less in each quarter, the grant date is the date the award is approved by our Chief Executive Officer.
	Stock-based awards generally vest 25% on the first anniversary of the date of grant, or for new hires, the first anniversary of their initial date of employment. Awards vest monthly thereafter on a straight-line basis over three years. Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 90 days from the last date of employment. In the event of an optionee’s death, disability, or retirement, the exercise period is 365 days from the last date of employment.
	Employee Stock Purchase Plan
	Under the terms of our 2009 Employee Stock Purchase Plan (the “ESPP”), eligible employees can purchase common stock through payroll deductions. The purchase price is equal to the closing price of our common stock on the first or last day of the offering period (whichever is less), minus a 15% discount. We use the Black-Scholes option-pricing model, in combination with the discounted employee price, in determining the value of ESPP expense to be recognized during each offering period. A participant may purchase a maximum of 50,000 shares of common stock during a six-month offering period, not to exceed $25,000 worth of stock on the offering date during each plan year.
	A total of 5.0 million shares of common stock are authorized for issuance under the ESPP. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the ESPP shall increase by an amount equal to the lesser of (i) 1 million shares or (ii) an amount determined by the ESPP administrator. However, in no event shall the number of shares of common stock available for future sale under the ESPP exceed 10.0 million shares, subject to capitalization adjustments occurring due to dividends, splits, dissolution, liquidation, mergers, or changes in control.
	Stock-Based Compensation Expense Summary
	We classify our stock-based compensation expense (inclusive of our 2009 Plan, ESPP, and 401(k) matching) in the accompanying Consolidated Statements of Operations, based on the department to which the recipient belongs. Stock-based compensation expense included within operating expenses for years ended December 31, 2013, 2012, and 2011 was as follows:


			Year Ended December 31,
			2013				2012			2011
	Selling, general and administrative		$	10,762			$	13,041		$	20,609
	Research and development			2,017				1,843			1,628

	Total		$	12,779			$	14,884		$	22,237

	Employee stock-based compensation expense for the years ended December 31, 2013, 2012, and 2011 was recognized (reduced for estimated forfeitures) on a straight-line basis over the vesting period. Forfeitures are estimated at the time of grant and prospectively revised if actual forfeitures differ from those estimates. We estimate forfeitures of stock options using the historical exercise behavior of our employees. For purposes of this estimate, we have applied an estimated forfeiture rate of 8%, 5%, and 5% for the years ended December 31, 2013, 2012, and 2011.
	Valuation Assumptions – Restricted Stock and Stock Options
	The grant-date fair value per share for restricted stock awards was based upon the closing market price of our common stock on the award grant-date.
	The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:


			Year Ended December 31,
			2013		2012		2011
	Expected option life (in years) (a)		4.95		4.5		4.93
	Risk-free interest rate (b)		0.35% - 0.78%		0.34% - 0.51%		0.82% - 2.4%
	Volatility (c)		58.3% - 71.5%		64.2% -73.6%		55.80%
	Dividend yield (d)		0%		0%		0%
	Weighted-average grant-date fair value per stock option		$4.66		$6.20		$2.65

	(a)	Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).
	(b)	Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options’ expected term).
	(c)	Measured using our historical stock price for a period equal to stock options’ expected term.
	(d)	We do not expect to declare any cash dividends in the foreseeable future.

	Stock Option Activity
	Stock option activity during the years ended December 31, 2013, 2012, and 2011 is as follows:


			Number of				Weighted-			Weighted-			Aggregate
			Shares				Average			Average			Intrinsic
							Exercise			Remaining			Value
							Price/Share			Contractual
										Term (Years)
	Outstanding — December 31, 2010			8,397,094			$	4.17
	Granted			3,622,150				7.92
	Exercised			(1,126,257	)			4.07					$	8,255	(1)
	Forfeited			(547,479	)			4.81
	Expired			(159,987	)			5.17

	Outstanding — December 31, 2011			10,185,521			$	5.46
	Granted			1,821,915				11.57
	Exercised			(1,287,430	)			4.52					$	11,500	(1)
	Forfeited			(316,825	)			7.93
	Expired			(3,916	)			7.69

	Outstanding — December 31, 2012			10,399,265			$	6.57
	Granted			2,041,300				8.92
	Exercised			(825,884	)			4.4					$	3,435	(1)
Forfeited			(202,882	)			8.22
Expired			(82,581	)			8.91

Outstanding — December 31, 2013			11,329,218			$	7.1			7		$	25,849	(2)

Vested (exercisable) — December 31, 2013			7,876,025			$	6.11			6.2		$	24,080	(2)

Unvested (unexercisable) — December 31, 2013			3,453,193			$	9.38			8.9		$	1,770	(2)


-1	Represents the total difference between our closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
-2	Represents the total difference between our closing stock price on the last trading day of 2013 and the stock option exercise price, multiplied by the number of in-the-money options as of December 31, 2013. The amount of intrinsic value will change based on the fair market value of our stock.
The following table summarizes information with respect to stock option grants as of December 31, 2013:


		Outstanding										Exercisable
Exercise Price		Granted Stock				Weighted-			Weighted-			Granted				Weighted-
		Options				Average			Average			Stock				Average
		Outstanding				Remaining			Exercise			Options				Exercise
						Contractual			Price			Exercisable				Price
						Life (Years)
$0.92 – 3.15			1,192,794				4.5		$	2.16			1,192,794			$	2.16
$3.55 – 4.95			1,924,904				5.9			4.23			1,865,794				4.23
$5.05 – 6.90			2,862,699				5.5			6.26			2,565,220				6.19
$7.00 – 8.99			2,329,167				8.2			8.17			1,147,138				8.26
$9.00 – 16.32			3,019,654				9.2			10.86			1,105,079				11.09

			11,329,218				7		$	7.1			7,876,025			$	6.11

As of December 31, 2013, there was unrecognized compensation expense of $12.4 million related to unvested stock options, which we expect to recognize over a weighted average period of 2.54 years.

Restricted Stock Activity
A summary of restricted stock activity is as follows:


		Number of				Weighted Average
		Restricted Stock				Fair Value per
		Awards				Share at Grant
						Date
Unvested as of December 31, 2010			359,500			$	3.96
Granted			1,781,000				12.48
Vested			(1,104,025	)			12.33
Forfeited			(83,950	)			4.78

Unvested — December 31, 2011			952,525				10.11
Granted			586,639				11.76
Vested			(472,160	)			10.26
Forfeited			(32,400	)			9.57

Unvested — December 31, 2012			1,034,604				11
Granted			523,800				8.74
Vested			(501,660	)			9.72
Forfeited			(49,625	)			10.6

Unvested — December 31, 2013			1,007,119			$	10.09


*	Represents our stock price on the vesting date multiplied by the number of vested shares.


		2013				2012			2011
Restricted stock expense		$	4,202			$	6,500		$	4,100
As of December 31, 2013, there was approximately $6.5 million of unrecorded expense related to issued restricted stock that will be recognized over an estimated weighted average period of 2.4 years.
401(k) Plan – Stock Matching Contribution
We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employee contributions, as summarized below:


		2013				2012			2011
Shares of common stock issued			99,359				56,254			65,889
Match contribution value**		$	860			$	691		$	593

**	Represents our stock price on the date of the stock match multiplied by the number of shares of common stock issued.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	7	STOCKHOLDERS’ EQUITY
	Authorized Stock
	On December 13, 2010, we filed the Certificate of Designation of Rights, Preferences and Privileges of Series B Junior Participating Preferred Stock with the Delaware Secretary of State which authorized 1.5 million shares to be designated as Series B Junior Participating Preferred Stock. On June 13, 2011, our stockholders approved an amendment to our Certificate of Incorporation to increase the authorized number of shares of our common stock from 100.0 million shares to 175.0 million shares. The amendment was filed with the Delaware Secretary of State on June 24, 2011. As of December 31, 2013, we also had 5.0 million shares of preferred stock authorized, of which 1.5 million shares were designated as Series B Junior Participating Preferred Stock and 2,000 shares were designated as Series E Convertible Voting Preferred Stock.
	Stockholder Rights Agreement
	On November 29, 2010, our Board of Directors approved a replacement rights agreement, effective December 13, 2010, that replaced the stockholder rights agreement which was originally adopted in 2000. This replacement rights agreement will extend until December 13, 2020. A stockholder rights agreement is designed to deter coercive, unfair, or inadequate takeovers and other abusive tactics that might be used in an attempt to gain control of the Company. A stockholder rights agreement will not prevent takeovers at a full and fair price, but rather is designed to deter coercive takeover tactics and to encourage anyone attempting to acquire the Company to first negotiate with our Board of Directors.
	Under the terms of the new Stockholder Rights Agreement, the rights become exercisable upon the earlier of 10 days after a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of our common stock or 10 business days after a tender offer has commenced that would result in a person or group beneficially owning 15% or more of our outstanding common stock. These rights could delay or discourage someone from acquiring our business, even if doing so would benefit our stockholders. We currently have no stockholders who own 15% or more of the outstanding shares of our common stock. Five days after the rights become exercisable, each right, other than rights held by the person or group of affiliated persons whose acquisition of more than 15% of our outstanding common stock caused the rights to become exercisable, will entitle its holder to buy, in lieu of shares of Series B Preferred Stock, a number of shares of our common stock having a market value of twice the exercise price of the rights. After the rights become exercisable, if we are a party to certain merger or business combination transactions or transfers 50% or more of our assets or earnings power (as defined), each right will entitle its holder to buy a number of shares of common stock of the acquiring or surviving entity having a market value of twice the exercise price of the right.
	Series E Preferred Stock
	In September 2003, we received gross cash proceeds of $20.0 million in exchange for the issuance of 2,000 shares of our Series E Convertible Voting Preferred Stock, convertible into 4.0 million shares of common stock. As of December 31, 2013 and 2012, 20 shares of Series E Preferred Stock were outstanding. No dividends are payable on the Series E Preferred Stock. Pursuant to certain provisions of the Certificate of Designation, Rights and Preferences of the Series E Preferred Stock, we have the option to redeem all of the unconverted Series E Preferred Stock outstanding at the end of a 20-day trading period if, among other things, in that period our common stock trades above $12.00 per share.
	In the event we are the subject of any voluntary or involuntary liquidation, dissolution or winding up, before any distribution of our assets shall be made to the common stockholders, the holders of the Series E Preferred Stock shall be entitled to receive a liquidation preference in an amount equal to 120% of the stated value per share plus any declared and unpaid dividends thereon.
	Common Stock Reserved for Future Issuance
	As of December 31, 2013, approximately 28.1 million shares of our common stock were issuable upon conversion or exercise of rights granted, or to be granted, as summarized below:


	Conversion of Series E Preferred Stock			40,000
	2018 Convertible Notes			11,400,000
	Exercise of issued employee stock options			11,329,218
	Exercise of issued warrants			445,000
	ESPP shares reserved			4,540,986
	Long-term retention and management incentive plan shares			346,500

	Total shares of common stock reserved for future issuances			28,101,704

	Warrant Activity
	We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on varying dates through December 2015. A summary of warrant activity is as follows:


			Number of			Weighted
			Shares			Average
						Exercise Price
	Outstanding — December 31, 2010			4,192,312		$	6.45
	Expired			(3,747,312	)		6.62

	Outstanding — December 31, 2011			445,000		$	5.04
	Exercised			(50,000	)		1.79

	Outstanding — December 31, 2012			395,000		$	5.45
	Granted			50,000			7.51

	Outstanding — December 31, 2013			445,000		$	6.39

	Exercisable — December 31, 2013			407,500		$	6.29

Net_Loss_Income_Per_Share

Net (Loss) Income Per Share	12 Months Ended
Net (Loss) Income Per Share	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Net (Loss) Income Per Share	'
	8	NET (LOSS) INCOME PER SHARE
	Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December 31, 2013, 2012, and 2011:


			Year Ended December 31,
			2013			2012		2011
	Net (loss) income		$	(62,134	)	$	94,201	$	49,931

	Weighted average shares - basic			60,729,128			58,588,916		53,272,767
	Net (loss) income per share - basic		$	(1.02	)	$	1.61	$	0.94

	Weighted average shares - diluted			60,729,128			64,637,256		57,959,714
	Net (loss) income per share - diluted		$	(1.02	)	$	1.46	$	0.86
	The following summarizes the amounts used in computing basic and diluted net income per share, for the years ended 2012 and 2011:


			Net Income			Weighted-		Net
			(numerator)			Average		Income
						Shares		Per Share
						Outstanding
						(Denominator)
	Year Ended December 31, 2012
	Basic net income per share:		$	94,201			58,588,916	$	1.61

	Diluted net income per share:
	Dilutive preferred shares						40,000
	Dilutive common stock options						4,749,299
	Incremental common stock assumed issued on exercise of in-the-money warrants						224,437
	Unvested restrictive stock awards						1,034,604

	Diluted net income per share		$	94,201			64,637,256	$	1.46



			Net Income			Weighted-		Net
			(numerator)			Average		Income
						Shares		Per Share
						Outstanding
						(Denominator)
	Year Ended December 31, 2011
	Basic net income per share:		$	49,931			53,272,767	$	0.94

	Diluted net income per share:
	Dilutive preferred shares						40,000
	Dilutive common stock options						4,185,224
	Change in common stock related to Targent and management incentive plan milestones, as if they had been issued at the beginning of the quarter earned						248,193
	Incremental common stock assumed issued on exercise of in-the-money warrants						200,656
	Unvested restrictive stock awards						12,874

	Diluted net income per share		$	49,931			57,959,714	$	0.86


	Our outstanding securities were excluded from the above calculation of net (loss) per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net (loss) per share in 2013:


			Year Ended December 31,
			2013			2012		2011
	2018 Convertible Notes			343,600			—		—
	Common stock options			2,934,625			—		—
	Restricted stock awards			1,007,119			—		—
	Common stock warrants			160,816			—		—
	Preferred stock			40,000			—		—

Total			4,486,160			—		—

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	9	FAIR VALUE MEASUREMENTS

	The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories (as described within Note 2 (x)):



			December 31, 2013
			Fair Value Measurements
			Level 1		Level 2		Level 3		Total

	Assets:
	Bank CDs		$	—	$	410	$	—	$	410
	Money market currency funds			—		100,395		—		100,395
	Mutual funds			—		3,061		—		3,061
	Deferred compensation investments, including life insurance cash surrender value			—		5,361		—		5,361
	Equity securities			3,593		—		—		3,593

			$	3,593	$	109,227	$	—	$	112,820

	Liabilities:
	Deferred executive compensation liability			—		3,949		—		3,949
	Deferred development costs			—		—		17,742		17,742
	Ligand Contingent Consideration			—		—		4,000		4,000
	Talon CVR			—		—		4,329		4,329

			$	—	$	3,949	$	26,071	$	30,020




			December 31, 2012
			Fair Value Measurements
			Level 1		Level 2		Level 3		Total

	Assets:
	Bank CDs		$	—	$	987	$	—	$	987
	Money market currency funds					11,698		—		11,698
	Mutual funds			—		2,323		—		2,323
	Deferred compensation investments, including life insurance cash surrender value			—		2,881		—		2,881
	Equity securities			2,480		—		—		2,480

			$	2,480	$	17,889	$	—	$	20,369

	Liabilities:
	Deferred executive compensation liability			—		2,365		—		2,365
	Deferred development costs			—		—		12,233		12,233
	Deferred payment contingency			—		—		2,287		2,287
	Ligand Contingent Consideration			—		—		—		—

			$	—	$	2,365	$	14,520	$	16,885


	We did not have any transfers between Levels 1 and 2 for all periods presented. The following presents a roll forward of our liabilities for which we utilize Level 3 inputs (see Note 2(x)) in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “accrued and deferred development costs, less current portion”. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.

	Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities, excluding acquisition related contingent consideration liabilities, approximate their related fair values due to their short-term nature.



			Fair Value Measurements of
			Unobservable Inputs (Level 3)
	Balance at December 31, 2011		$	—
	Transfers in (out)			—
	Deferred development costs			12,233
Deferred payment contingency			2,287

Balance at December 31, 2012			14,520
Transfers in (out)			—
Deferred development costs (see Note 13)			5,509
Deferred payment contingency (see Note 13)			(2,287	)
Ligand Contingent Consideration (see Note 10(b))			4,000
Talon CVR (see Note 10(a))			4,329

Balance at December 31, 2013		$	26,071

Business_Combinations

Business Combinations	12 Months Ended
Business Combinations	Dec. 31, 2013
Business Combinations [Abstract]	'
Business Combinations	'
	10	BUSINESS COMBINATIONS
	(a) Acquisition of Talon Therapeutics, Inc.
	Talon Acquisition Overview
	On July 16, 2013, we entered into a Securities Purchase Agreement with Talon Therapeutics, Inc. (“Talon”), whereby, on July 17, 2013, we purchased all of its then outstanding shares of common stock. Through the acquisition of Talon, we gained worldwide rights to MARQIBO, an FDA-approved drug that we believe complements our other hematology and oncology products.
	Since July 17, 2013, the results of operations of the former Talon business have been included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2013. From July 17, 2013 through December 31, 2013, our revenue derived from the former Talon business was approximately $1.3 million. We had nominal earnings from the Talon business during this period.
	The Talon purchase consideration comprised of (i) an aggregate upfront cash amount of $11.3 million, (ii) issuance of 3.0 million shares of our common stock, then equivalent to $26.3 million (based on a closing price of $8.77 per share on July 17, 2013), and (iii) the issuance of contingent value rights (“CVR”) initially valued by us at $6.5 million.
	The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs – see Note 3 (x)). The CVR has a maximum payout of $195.0 million if all sales and regulatory approval milestones are achieved, as summarized below:

		•		$5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year

		•		$10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year

		•		$25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year

		•		$50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year

		•		$100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year

		•		$5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion
	Direct Costs of the Talon Acquisition
	Our direct costs of the Talon acquisition included employee severance, banker, legal, and accounting fees which aggregated to $5.7 million. This amount is included in “selling, general and administrative expenses” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.
	Consideration Transferred
	The Talon acquisition purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based upon their estimated fair value at the acquisition date. The following table summarizes the purchase price:


	Cash consideration		$	11,300
	CVR			6,500
	Spectrum shares of common stock			26,300

	Total purchase consideration		$	44,100


	Fair Value Estimate of Assets Acquired and Liabilities Assumed
	Under the purchase method of accounting, the total purchase consideration is allocated to Talon net tangible and intangible assets acquired and liabilities assumed based on the estimated fair values as of the acquisition date. The following table summarizes the estimated fair value of the net assets acquired on July 17, 2013:


	Cash and equivalents		$	131
	Inventory			611
	Prepaid expenses and other current assets			109
	Property and equipment			30
	Identifiable intangible assets			44,500


	Total assets acquired			45,381


	Accounts payable & accrued liabilities			5,231
	Deferred tax liability			6,576


	Total liabilities assumed			11,807

	Net assets acquired		$	33,574



	Goodwill		$	10,526

	The acquired intangible assets consisted of developed technology and in-process research and development (“IPR&D”) for MARQIBO treatment of acute lymphoblastic leukemia (“ALL”) and MARQIBO treatment of non-Hodgkin’s lymphoma (“NHL”) as follows in the table below:


			Value of			Amortization
			Intangible			Period*
Assets
Acquired
Developed technology —MARQIBO for ALL			$	26,900			13 years
IPR&D —MARQIBO for NHL				17,600				-1

Total identifiable intangible assets		$	44,500


*	Recognized on a straight-line basis.
-1	IPR&D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&D is not amortized during this period, but rather tested for impairment.
The fair value of the acquired IPR&D technology assets was estimated using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts.
Goodwill
Goodwill presented above of $10.5 million represents the difference of the Talon business purchase price of $44.1 million minus the net assets acquired of $33.6 million. This goodwill includes benefits that we believe will result from combining the operations of Talon with ours, as well as the know-how associated with the MARQIBO compounds for future product development. In accordance with applicable GAAP, we will not amortize goodwill associated with the Talon acquisition, though it will be subjected to annual impairment testing. This goodwill is not deductible for income tax purposes.

Supplemental Pro Forma Financial Information
The following unaudited pro forma financial information is presented to reflect the results of the Company’s consolidated operations for the years ended December 31, 2013 and 2012, as if the acquisition of Talon had occurred on January 1, 2012. To reflect the combined businesses, adjustments have been made to exclude one-time transaction costs and employee severance costs that were directly associated with the Talon acquisition. These pro forma results have been prepared for informational purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January 1, 2012, and may not be indicative of future operating results.


		Year Ended December 31,
		2013			2012
Pro Forma Total revenues		$	155,854		$	267,707
Pro Forma Total costs and operating expenses			200,651			210,433
Pro Forma Net (loss) income			(68,146	)		57,274
Pro Forma Net (loss) income per share – basic		$	(1.12	)	$	0.98
Pro Forma Net (loss) income per share – diluted		$	(1.12	)	$	0.89
Talon CVR Fair Value as of December 31, 2013
The CVR fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.


		Fair Value
		of Talon
		CVR
July 17, 2013		$	6,500
Fair value adjustment for year ended December 31, 2013			(2,171	)

December 31, 2013		$	4,329

(b) Acquisition of Rights to Captisol-Enabled ® MELPHALAN
Overview of Acquisition of Rights to C-E MELPHALAN
On March 8, 2013, we completed the acquisition of exclusive global development and commercialization rights to Captisol-enabled ®, propylene glycol-free MELPHALAN (“C-E MELPHALAN”) from CyDex Pharmaceuticals, Inc. a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”). C-E MELPHALAN is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April 1, 2013. We are required to pay Ligand additional amounts up to an aggregate $66.0 million, upon the achievement of certain regulatory milestones and net sales thresholds (“Ligand Contingent Consideration”). We also must pay royalties in the range of 15% to 25% on net sales of licensed products in all territories.
We accounted for the acquisition of these rights as a business combination, using the acquisition method of accounting. This requires that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. Aggregate transaction costs of $15,000 are included in “selling, general and administrative expenses” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.
Consideration Transferred
The acquisition-date fair value of the consideration transferred consisted of the following items:


Cash consideration		$	3,000
Ligand Contingent Consideration			4,700

Total purchase consideration		$	7,700


Fair Value Estimate of Asset Acquired and Liability Assumed
The total purchase consideration is allocated to the acquisition of the tangible and intangible assets acquired and liabilities assumed. These amounts are based on their estimated fair values as of the closing date. The allocation of the total purchase price to the net assets acquired is as follows:


IPR&D—C-E MELPHALAN rights		$	7,700

Acquired IPR&D is an intangible asset that is classified as indefinite-lived until the completion or abandonment of the associated R&D effort, and is subject to impairment testing. C-E MELPHALAN rights will be amortized over an estimated useful life to be determined at the date the project is complete.
We estimated the fair value of the in-process research and development using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts. The fair value estimate took into account our estimates of future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights, and included estimated cash flows of approximately 10 years and a discount rate of approximately 25%.
The fair value of the contingent consideration liability assumed was determined using the probability of success and the discounted cash flow method of the income approach (representing unobservable inputs and are therefore classified as Level 3 inputs – see Note 3(x)), which assumes that FDA approval of C-E MELPHALAN will occur on or about December 31, 2015. Upon receipt of FDA approval, we will be obligated to make a milestone payment of $6.0 million to Ligand.
We do not consider this acquisition to represent a material business combination; accordingly, we have not presented pro forma results of our combined operations that are otherwise required.
Ligand Contingent Consideration Fair Value as of December 31, 2013
The Ligand Contingent Consideration fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to Ligand Contingent Consideration fair value are recognized within “fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.


		Fair Value of
		Ligand
		Contingent
		Consideration
March 8, 2013		$	4,700
Fair value adjustment for year ended December 31, 2013			(700	)

December 31, 2013		$	4,000

(c) Allos Acquisition
We acquired Allos Therapeutics, Inc. (“Allos”) on September 5, 2012, which was accounted for as a business combination. Our total consideration for this acquisition was $205.2 million, through which we acquired FOLOTYN development technology and FOLOTYN distribution rights.

Revolving_Line_of_Credit

Revolving Line of Credit	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Revolving Line of Credit	'
	11	REVOLVING LINE OF CREDIT

	We entered into a credit agreement on September 5, 2012 with Bank of America, N.A, as the administrative agent and Wells Fargo Bank, N.A, as an initial lender, as amended July 16, 2013 (the “Credit Agreement”). The Credit Agreement provided us with a committed $50.0 million revolving line of credit facility (the “Credit Facility”). The Credit Facility was to expire on September 5, 2014, though we repaid it in full, then immediately terminated it on December 20, 2013 in connection with the sale and issuance of our 2018 Convertible Notes.



	The Credit Facility bore interest, at our election, at a rate equal to the London Interbank Offer Rate (LIBOR), or the base rate, plus an applicable margin (2.75% to 4.25%, dependent on a defined liquidity ratio).

	We incurred $1.0 million in related loan costs and fees in securing the Credit Facility, which were capitalized and recognized within “other assets” on our accompanying Consolidated Balance Sheets. This amount was amortized through “interest expense” to the accompanying Consolidated Statements of Operations, using the effective interest method, initially over the term of the Credit Facility, though the remaining unamortized portion was fully expensed in December 2013 when it was repaid and terminated.

	An unused line fee was payable quarterly in an amount ranging from 0.375% to 0.625% of the sum of the average daily unused portion of the facilities during any quarter based upon consolidated leverage ratio as at the last test date. A customary fee was also payable to the administrative agent on an annual basis in advance.

	We recognized $1.2 million, $0.5 million, and $-0- in 2013, 2012, and 2011, respectively, within “interest expense” for this retired Credit Facility on the accompanying Consolidated Statements of Operations.

Convertible_Senior_Notes

Convertible Senior Notes	12 Months Ended
Convertible Senior Notes	Dec. 31, 2013
Text Block [Abstract]	'
Convertible Senior Notes	'
	12	CONVERTIBLE SENIOR NOTES
	On December 17, 2013, we entered into an agreement for the sale of $120.0 million aggregate principal amount of 2.75% Convertible Senior Notes due December 2018 (the “2018 Convertible Notes”). The 2018 Convertible Notes are convertible into shares of our common stock at a conversion rate of 95 shares per $1,000 principal amount of the 2018 Convertible Notes, totaling 11.4 million common shares if fully converted. The in-the-money conversion price is equivalent to $10.53 per common share. The conversion rate and conversion price is subject to adjustment under certain limited circumstances, as defined in the Indenture. The 2018 Convertible Notes bear interest at a rate of 2.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2014. The 2018 Convertible Notes will mature and become payable on December 15, 2018, subject to earlier conversion into common stock at the holders’ option.
	On December 23, 2013 net proceeds from the sale of the 2018 Convertible Notes were $115.4 million, after deducting banker and professional fees of $4.6 million. We used a portion of these net proceeds to simultaneously enter into “bought call” and “sold warrant” transactions with Royal Bank of Canada (collectively, the “Note Hedge”). We recorded the Note Hedge on a net cost basis of $13.1 million, as a reduction to “additional paid-in capital” in our accompanying Consolidated Balance Sheets. Under applicable GAAP, the Note Hedge transaction is not expected to be marked-to-market through earnings or comprehensive income in future reporting periods.
	We entered into Note Hedge transactions to reduce the potential dilution to our common stock and/or offset any cash payments that we are required to make in excess of the principal amount, upon conversion of the 2018 Convertible Notes (in the event that the market price of our common stock is greater than the conversion price). The strike price of the “bought call” is equal to the conversion price and conversion rate of the 2018 Convertible Notes, matching the 11.4 million common shares the 2018 Convertible Notes may be converted into. The strike price of our “sold warrant” is $14.03 per share of our common stock, and is also for 11.4 million common shares.
	As of December 31, 2013, the 2018 Convertible Notes were not convertible. Prior to June 15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after March 31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; or (4) at any time we have not received stockholder approval, as that term is defined in the Indenture governing the 2018 Convertible Notes. On and after June 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Convertible Notes at any time, regardless of the foregoing circumstances.

	We initially may only settle conversions of the 2018 Convertible Notes by delivering shares of our common stock. However, if we obtain stockholder approval in accordance with applicable NASDAQ rules, we may settle conversions of the 2018 Convertible Notes by paying or delivering, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at our election.
	The carrying values of the 2018 Convertible Notes as of December 31, 2013 is summarized as follows:


	Principal amount		$	120,000
	(Less): Unamortized debt discount (amortized through December 2018)			(28,520	)

	December 31, 2013 net carrying amount of 2018 Convertible Notes		$	91,480

	The following table sets forth the components of total “interest expense” recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the year ended December 31, 2013:


	Contractual coupon interest expense		$	73
	Amortization of debt issuance costs			43
	Accretion of debt discount			101

	Total		$	217


	Effective interest rate			8.59	%

Mundipharma_Agreement

Mundipharma Agreement	12 Months Ended
Mundipharma Agreement	Dec. 31, 2013
Text Block [Abstract]	'
Mundipharma Agreement	'
	13	MUNDIPHARMA AGREEMENT

	As the result of Allos becoming our wholly-owned subsidiary, effective September 5, 2012, we assumed obligations under a strategic collaboration agreement with Mundipharma (the “Mundipharma Collaboration Agreement”). Under the Mundipharma Collaboration Agreement, we retained full commercialization rights for FOLOTYN in the U.S. and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries in the world (the “Mundipharma Territories”).

	On May 29, 2013, the Mundipharma Collaboration Agreement was amended and restated (the “Amended Munipharma Collaboration Agreement”), in order to modify: (i) the scope of the licensed territory, (ii) milestone payments, (iii) royalty rates, and (iv) development obligations. In connection with the Amended Munipharma Collaboration Agreement, we received a one-time $7.0 million payment from Mundipharma for certain research and development activities to be performed by us.

	As a result, (i) Europe and Turkey were excluded from Mundipharma’s commercialization territory, (ii) we may now receive potential regulatory milestone payments of up to $16.0 million and commercial progress and sales-dependent milestone payments of up to $107.0 million, (iii) we will receive tiered double- digit royalties based on net sales of FOLOTYN within Mundipharma’s licensed territories, and (iv) we and Mundipharma will bear our own FOLOTYN development costs. We recorded the fair value of the related drug development liability of $12.3 million as of September 2012, using the discounted cash flow method of the income approach. The fair value of this liability was determined to be $17.7 million as of December 31, 2013 (inclusive of the $7.0 million payment from Mundipharma) and is included in current and long-term “drug development liability” within the accompanying Consolidated Balance Sheets. This value includes our assumptions about personnel needed to perform these research and development activities, third party costs for projected clinical trial enrollment, and patient treatment-related follow up through approximately 2031.

	We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our Consolidated Statements of Operations.



			Year Ended December 31,
			Drug			Drug			Total Drug
			Development			Development			Development
			Liability,			Liability,			Liability –
			Current –			Long Term –			FOLOTYN
			FOLOTYN			FOLOTYN
	Balance at December 31, 2012		$	856		$	11,377		$	12,233
	Transfer from long term to current			3,620			(3,620	)		—
	Amended agreement payment receipt			—			7,000			7,000
	(Less): Expenses incurred			(1,357	)		(134	)		(1,491	)

	Balance at December 31, 2013		$	3,119		$	14,623		$	17,742

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	14	COMMITMENTS AND CONTINGENCIES
	(a) Facility and Equipment Leases
	We lease our principal executive office in Henderson, Nevada under a non-cancelable operating lease expiring April 30, 2014. We also lease our research and development and administrative facility in Irvine, California under a non-cancelable operating lease expiring May 31, 2019, in addition to several other administrative office leases. Each lease agreement contains certain scheduled rent increases which are accounted for on a straight-line basis. Our total rental expense in 2013, 2012, and 2011 was $1.2 million, $0.9 million, and $0.7 million, respectively.
	Our future minimum lease payments are as follows:


	Year ending December 31,		Operating Lease
			Minimum
			Payments
	2014		$	849
	2015			950
	2016			892
	2017			843
	2018			868

			$	4,402

	(b) Licensing Agreements, Co-Development Agreements, and Milestone Payments
	We are developing almost all of our drug candidates pursuant to license agreements that provide us with rights in certain territories, among other things, to develop, sublicense, manufacture and sell the drugs. We are generally required to use commercially reasonable efforts to develop the drugs, and are generally responsible for all development, patent filing and maintenance, sales and marketing and liability insurance costs. We are also obligated to make certain milestone payments to the licensors if we successfully reach development and regulatory milestones specified in the license agreements. In addition, we are obligated to pay royalties and, in some cases, milestone payments based on our net sales.
	The potential contingent development and regulatory milestone obligations under all of our licensing agreements are generally tied to progress through the various regulatory authorities’ approval process, which approval significantly depends on positive clinical trial results.
	Our most significant of these agreements are listed and summarized below:
	(i) ZEVALIN licensing and development in the U.S.
	In December 2008, we acquired rights to commercialize and develop ZEVALIN in the U.S. as the result of a transaction with Cell Therapeutics, Inc. (“CTI”). Pursuant to the transfer of the ZEVALIN assets from CTI to RIT Oncology LLC (“RIT”), in December 2008, RIT assumed certain agreements with various third parties related to ZEVALIN intellectual property. These agreements relate to the manufacture, use, and sale of ZEVALIN in the U.S.

	In accordance with the terms of such agreements, RIT is required to meet specified payment obligations including a commercial milestone payment to Corixa Corporation of $5.0 million based on ZEVALIN sales in the U.S., which has not yet been met, as well as U.S. net sales-based royalties of low to mid-single digits to Genentech, Inc. and mid-single digits to Corixa Corporation.
	(ii) Asset Purchase Agreement between CTI and Biogen, ZEVALIN U.S.
	In connection with the joint venture arrangement with CTI, we entered into an amendment to the original asset purchase agreement between CTI and Biogen, modifying future milestone payments. Pursuant to the terms of the agreement, as amended, (i) upon the achievement of the specified FDA approval milestone, which was achieved in 2009, RIT (as successor to CTI) paid Biogen an additional amount of $5.5 million, (ii) RIT may be required to make an additional $10.0 million milestone payment upon the achievement of an additional FDA approval milestone, and (iii) RIT is required to make yearly royalty payments determined as a mid-single to mid-teen digits percentage of yearly net sales for the preceding year, increasing with the passage of time. The agreement has an indefinite term and is no longer subject to termination; provided, however, that the royalty obligations automatically terminate upon the latest to occur of expiration of the subject patents, the sale by a third party of a biosimilar product in the U.S. or December 31, 2015. CTI’s rights and obligations, including its payment obligations to Biogen for royalties on net sales of ZEVALIN and an additional regulatory milestone payment, under both the CTI/Biogen Agreement and the amendment were assigned to and assumed by RIT in connection with the closing of the joint venture transaction.
	(iii) License and Asset Purchase Agreement with Bayer Pharma, ZEVALIN Ex-U.S.
	On April 1, 2012, through our subsidiary, Spectrum Pharmaceuticals Cayman, L.P., we completed the acquisition of licensing rights to market ZEVALIN outside of the U.S., referred to as the ZEVALIN Ex-US Rights, from Bayer Pharma AG, or Bayer.
	We currently market ZEVALIN in the U.S. and this agreement expanded our commercial efforts to the rest of the world. ZEVALIN is currently approved in more than 40 countries outside the U.S. for the treatment of B-cell non-Hodgkin lymphoma, including countries in Europe, Latin America and Asia. In consideration for the rights granted under the agreement, concurrent with the closing, we paid Bayer a one-time fee of Euro 19.0 million, and will pay Bayer royalties based on a mid-teen digits percentage of net sales of the licensed products in all territories worldwide except the U.S. Unless earlier terminated, the term of the agreement continues until the expiration of our royalty payment obligations which, in turn, run until the last-to-expire patent covering the sale of a licensed product in the relevant country or 15 years from the date of first commercial sale of the licensed product in such country, whichever is longer.
	(iv) Amended and Restated License Agreement with Merck & Cie AG, FUSILEV
	In May 2006, we amended and restated a license agreement with Merck & Cie AG, a Swiss corporation, which we assumed in connection with the acquisition of the assets of Targent. Pursuant to the license agreement with Merck & Cie, we obtained the exclusive license to use regulatory filings related to FUSILEV and a non-exclusive license under certain patents and know-how related to FUSILEV to develop, make, use, and sell FUSILEV in the field of oncology in North America. In addition, we have the right of first opportunity to negotiate an exclusive license to manufacture, use, and sell FUSILEV products outside the field of oncology in North America. Also, under the terms of the license agreement, we paid Merck & Cie $0.1 million for the achievement of FDA approval of an injectable form of FUSILEV. Merck & Cie is also eligible to receive a $0.2 million payment upon achievement of FDA approval of an oral form of FUSILEV, in addition to royalties in the mid-single digits based on a percentage of net sales. The term of the license agreement is determined on a product-by-product and country-by-country basis until royalties are no longer owed under the license agreement. The license agreement expires in its entirety after the date that we no longer owe any royalties to Merck & Cie. We have the unilateral right to terminate the license agreement, in its entirety or on a product-by-product or country-by-country basis, at any time for any reason.
	(v) Asset Purchase Agreement with Targent, Inc., FUSILEV
	In March 2006, we entered into an Asset Purchase Agreement with Targent, Inc. (“Targent”). As part of the consideration for the purchase of certain assets, we agreed to pay milestone payments to Targent upon the achievement of certain regulatory events as well as for certain sales levels for FUSILEV within a calendar year. In connection with the achievement of the FDA approval milestone in April 2011, we issued an aggregate of 0.7 million shares of our common stock to certain of Targent’s stockholders. We capitalized $6.3 million associated with this milestone as an amortizable intangible asset.

	In addition, in connection with the achievement of the first sales milestone in May 2011, we issued 0.6 million shares of our common stock to certain of Targent’s stockholders. In September 2011, we achieved the second and final sales milestone and paid $5.0 million. We capitalized an aggregate $10.0 million associated with these milestones as amortizable intangible assets.
	(vi) License Agreement with Sloan-Kettering Institute, SRI International and Southern Research Institute, FOLOTYN
	In December 2002, Allos entered into the FOLOTYN License Agreement with Sloan-Kettering Institute for Cancer Research, SRI International, and Southern Research Institute. As a result of Allos becoming our wholly owned subsidiary effective September 5, 2012, we are bound by the FOLOTYN License Agreement under which we obtained exclusive worldwide rights to a portfolio of patents and patent applications related to FOLOTYN and its uses. Under the terms of the FOLOTYN License Agreement, we are required to fund all development programs and will have sole responsibility for all commercialization activities. In addition, we pay the licensors royalties based on worldwide graduated annual levels of net sales of FOLOTYN, or sublicense revenues arising from sublicensing the product, if and when such sales or sublicenses occur. Royalties are 8% of annual worldwide sales up to $150.0 million; 9% of annual worldwide sales of $150.0 million through $300.0 million; and 11% of annual worldwide sales in excess of $300.0 million.
	(vii) License Agreement with Cydex Pharmaceuticals, Inc., Captisol-enabled, Propyleneglycol-free MELPHALAN
	On March 8, 2013, we completed the acquisition of exclusive global development and commercialization rights to C-E MELPHALAN from Ligand (see Note 10(b)). This product candidate is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April 1, 2013. We are required to pay Ligand additional amounts of up to $66.0 million, upon achievement of certain regulatory milestones and net sales thresholds, and royalties in the range of 15% to 25% on net sales of licensed products in all territories.
	(viii) Exclusive Development and Commercialization Collaboration Agreement with Allergan, APAZIQUONE
	In October 2008, we signed an exclusive development and commercialization collaboration agreement with Allergan for APAZIQUONE. Pursuant to the terms of the agreement, Allergan paid us an up-front non-refundable $41.5 million at closing and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones.
	On January 29, 2013, we entered into a second amendment to the license, development, supply and distribution agreement with Allergan to amend the agreement and reacquire the rights originally licensed to Allergan in the U.S., Europe, and other territories in exchange for a tiered single-digit royalty on certain products containing APAZIQUONE, and relieved Allergan of its obligations for development, commercialization and other activities. As a result of this amendment to the agreement, Allergan has no remaining obligations to us, and we have no remaining performance obligations to them. However, we are obligated to pay Allergan a tiered single-digit royalty not to exceed mid-single digits based upon the net sales, when and if earned, of certain products containing APAZIQUONE in specified territories. Additionally, we are obligated to pay any royalties or other payments due to certain licensors of underlying intellectual property, as well as to provide indemnification of Allergan for claims arising from the manufacture, development, or commercialization of pharmaceutical products containing APAZIQUONE by us.
	(ix) Collaboration Agreement with Nippon Kayaku Co. LTD., APAZIQUONE
	In November 2009, we entered into a collaboration agreement with Nippon Kayaku Co., LTD. (“Nippon Kayaku”) for the development and commercialization of APAZIQUONE in Asia, except North and South Korea (the “Nippon Kayaku Territory”). In addition, Nippon Kayaku received exclusive rights to APAZIQUONE for the treatment of non-muscle invasive bladder cancer in Asia (other than North and South Korea), including Japan and China. Nippon Kayaku will conduct APAZIQUONE clinical trials in the Nippon Kayaku Territory pursuant to a development plan. Further, Nippon Kayaku will be responsible for all expenses relating to the development and commercialization of APAZIQUONE in the Nippon Kayaku Territory.
	Pursuant to the terms of this agreement, Nippon Kayaku paid Spectrum an upfront fee of $15.0 million and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones. Under the terms of the agreement, we are entitled to payment of $10.0 million and $126.0 million upon achievement of certain regulatory and commercialization milestones, respectively. Also, Nippon Kayaku has agreed to pay us royalties based on a percentage of net sales of the subject products in the defined territory in the mid-teen digits.
	Our license agreement with Nippon Kayaku provides for payments to us upon the achievement of development milestones, such as the completion of clinical trials or regulatory submissions, approvals by health authorities, and commercial launches of drug candidates. Given the challenges inherent in developing and obtaining approval for drug products and in achieving commercial launches, there was substantial uncertainty whether any such milestones would be achieved at the time of execution of such license agreement. We expect to recognize as revenue future payments received from such milestones only if achieved.
	(x) Licensing and Collaboration Agreement with TopoTarget, BELEODAQ
	In February 2010, we entered into a licensing and collaboration agreement with TopoTarget A/S (“TopoTarget”), as amended in October 2013, for the development and commercialization of BELEODAQ. The agreement provides that we have the exclusive right to make, develop, and commercialize BELEODAQ in North America and India, with an option for China.
	Under continuing terms, all development, including studies, will be conducted under a joint development plan. We have final decision-making authority for all developmental activities in North America and India (and China upon exercise of its option). TopoTarget has final decision-making authority for all developmental activities in all other jurisdictions. We are responsible for future costs of the ongoing registrational PTCL trial. We and TopoTarget will conduct future planned clinical trials pursuant to the joint development plan, of which we will fund 70% of the development costs, and TopoTarget will fund 30%.
	We will each pay 50% of the costs for chemical, pharmaceutical and other process development related to the manufacturing of the product that are incurred with a mutually agreed upon budget in the joint development plan. We have the right to manufacture clinical and commercial supplies of BELEODAQ. TopoTarget is obligated to purchase its BELEODAQ requirements from us on a cost plus basis.
	Pursuant to the terms of this agreement, we paid TopoTarget an upfront fee of $30.0 million in 2010. In addition, on the successful achievement of certain development, regulatory and sales milestones, we are obligated to issue 1.0 million shares of our common stock (subject to certain resale conditions) and pay TopoTarget up to $313.0 million. In February 2014, the first of these milestones was met, resulting in the issuance of 1.0 million shares of our common stock and the payment of $10.0 million to TopoTarget (see Note 17). We will pay TopoTarget future royalties in the mid-teen digits based on net sales of BELEODAQ in the defined territory.
	The agreement will continue until the expiration of the last royalty payment period in the last country in the defined territory with certain provisions surviving, unless earlier terminated in accordance with its terms. We may terminate this agreement with 180 days notice to TopoTarget. We may also terminate immediately upon a prohibition on the use of the subject product or clinical hold by the FDA. TopoTarget may also terminate immediately in the event of a challenge (without TopoTarget’s consent) by us of the patents that cover the product.
	(xi) Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Company, SPI-2012
	In late January 2012, we entered into a co-development and commercialization agreement with Hanmi Pharmaceutical Company, (“Hanmi”), for SPI-2012, formerly known as “LAPS-GCSF”, a drug for the treatment of chemotherapy induced neutropenia based on Hanmi’s proprietary LAPSCOVERY™ Technology. In consideration for the rights granted to us under the co-development and commercialization agreement with Hanmi, we paid Hanmi a fee which is included in “research and development expense” in the accompanying Consolidated Statements of Operations because the technology has not yet achieved regulatory approval. Under the terms of the agreement, we will share the costs and expenses of the study with Hanmi, although we will have primary responsibility for them. If SPI-2012 is ultimately commercialized by us, we will have worldwide rights except for Korea, China and Japan upon payment of fees and milestone payments related to further development, regulatory approvals and sales targets.
	(c) Service Agreements
	In connection with the research and development of our drug products, we have entered into contracts with numerous third party service providers, such as radio-pharmacies, distributors, clinical trial centers, clinical research organizations, data monitoring centers, and with drug formulation, development and testing laboratories. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on achievement of certain events specified in the agreements, such as contract execution, reservation of service or production capacity, actual performance of service, or the successful accrual and dosing of patients.
	At each period end, we accrue for all services received, with such accruals based on factors such as estimates of work performed, patient enrollment, completion of patient studies and other events. We are in a position to accelerate, slow-down or discontinue any or all of the projects that we are working on at any given point in time. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would be limited to the extent of the work completed. Generally, we are able to terminate these contracts due to the discontinuance of the related project(s) and thus avoid paying for the services that have not yet been rendered and our future purchase obligations would reduce accordingly.
	(d) Supply Agreements
	We have entered into certain supply agreements, or have issued purchase orders, which require us to make minimum purchases from vendors for the manufacture of our products. These commitments do not exceed our planned commercial requirements, and the contracted prices do not exceed their fair market value.
	(e) Employment Agreements
	We have entered into employment agreements with certain of our officers and other “key employees” under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.
	(f) Deferred Compensation Plan
On September 2, 2011, the Board of Directors approved the Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”). The DC Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. The DC Plan is administered by the Compensation Committee of our Board of Directors. The DC Plan is intended to be an unfunded plan which is maintained primarily to provide deferred compensation benefits for a select group of our employees, as selected by the DC Plan administrator (the “DC Participants”). Under the DC Plan, we provide the DC Participants with the opportunity to make annual elections to defer up to a specified amount or percentage of their eligible cash compensation, as established by the DC Plan administrator, and we have the option to make discretionary contributions. At December 31, 2013 and 2012, DC Plan deferrals and contributions totaling $3.9 million and $2.4 million, respectively, are included as a liability in the accompanying Consolidated Balance Sheets.
(g) Litigation
We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims.
We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition.
We are presently responding to Abbreviated New Drug Applications (“ANDAs”) filed by companies seeking to launch generic forms of FUSILEV and to certain shareholder suits that purportedly stem from our March 12, 2013 press release, in which we announced anticipated changes in customer ordering patterns of FUSILEV. These complaints allege that, as a result of the March 12, 2013 press release, our stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of our stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.

FUSILEV ANDA Litigation
On January 20, 2012 and February 17, 2012, respectively, we filed suit against Sandoz Inc. and Innopharma Inc, respectively following Paragraph IV certifications in connection with their filing separate ANDAs, to manufacture a generic version of FUSILEV. We filed the lawsuits in the U.S. District Court for the Districts of Nevada and Delaware seeking to enjoin the approval of their ANDAs plus recovery of our fees and costs incurred in such matters. On December 9, 2013, three Mylan entities collaborating with Innopharma were joined to Innopharma case. While we believe our patent rights are strong, the ultimate outcome of these cases is uncertain.
Shareholder Litigation
John Perry v. Spectrum Pharmaceuticals, Inc. et al. (Filed March 14, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00433-LDG-CWH. This putative consolidated class action raises substantially identical claims and allegations against defendants Spectrum Pharmaceuticals, Inc., Dr. Rajesh C. Shrotriya, Brett L. Scott, and Joseph Kenneth Keller. The alleged class period is August 8, 2012 to March 12, 2013. The lawsuits allege a violation of Section 10(b) of the Securities Exchange Act of 1934 against all defendants and control person liability, as a violation of Section 20(b) of the Securities Exchange Act of 1934, against the individual defendants. The claims purportedly stem from the Company’s March 12, 2013 press release, in which it announced that it anticipated a change in ordering patterns of FUSILEV. The complaints allege that, as a result of the March 12, 2013 press release, the Company’s stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of Company stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.
Timothy Fik v. Rajesh C. Shrotriya, et al. (Filed April 11, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00624-JCM-CWH); Christopher J. Watkins v. Rajesh C. Shrotriya, et al. (Filed April 22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00684-JCM-VCF); and Stefan Muenchhagen v. Rajesh C. Shrotriya, et al. (Filed May 28, 2013; Case Number 2:2013-cv-00942-APG-PAL). These derivative complaints are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum against certain current and former directors and officers. The complaints generally allege breaches of fiduciary based on conduct relating to the events alleged in the consolidated Perry action. The complaints seek compensatory damages, corporate governance reforms, restitution and disgorgement of defendants’ alleged profits, and costs and fees. On May 15, 2013, the court entered a consolidation order staying the actions pending resolution of the federal securities class action.
Hardik Kakadia v. Rajesh C. Shrotriya, et al. (Filed April 23, 2013 in the Eighth Judicial District Court of the State of Nevada in and for Clark County; Case Number A-13-680643-B); and Joel Besner v. Rajesh C. Shrotriya, et al. (Filed May 31, 2013; Case Number A-13-682668-C) (collectively the “State Derivative Actions”). These consolidated State Derivative Actions are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum Pharmaceuticals, Inc. and are substantially similar to the consolidated federal derivative actions.
(h) SEC Subpoena
On April 1, 2013, we received a subpoena from the SEC for documents pursuant to a formal order of investigation. The subpoena followed our March 12, 2013 announcement that we anticipated a change in customer ordering patterns of FUSILEV. We continue to cooperate with this SEC investigation, though we cannot predict its outcome, or the timing of resolution.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	15	INCOME TAXES
	The components of (loss) income before (provision) benefit for income taxes are as follows:


			For the Years Ended
			December 31,
			2013				2012				2011

	United States		$	(30,437	)		$	82,165			$	53,834
	Foreign			(6,199	)			(2,235	)			(199	)

	Total		$	(36,636	)		$	79,930			$	53,635


	The provision (benefit) for income taxes consist of the following:


			For the Years Ended
			December 31,
			2013				2012				2011
	Current:
	Federal		$	(8,357	)		$	16,222			$	1,255
	State			(691	)			3,412				2,449
	Foreign			—				—				—

			$	(9,048	)		$	19,634			$	3,704
	Deferred:
	Federal			36,183				(24,013	)			—
	State			(1,637	)			(9,892	)			—
	Foreign			—				—				—

				34,546				(33,905	)			—
	Total income tax provision (benefit)		$	25,498			$	(14,271	)		$	3,704

	The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:


			2013				2012				2011
	Tax provision (benefit) computed at the federal statutory rate		$	(12,822	)		$	27,975			$	18,250
	State tax, net of federal benefit			(246	)			2,442				2,918
	Expired tax attributes			—				—				385
	Research credits			(2,254	)			(2,129	)			(1,464	)
	Benefits from credit study			—				(4,148	)			—
	Common stock warrant liability			—				—				1,186
	Transaction costs			880				1,497				—
	Officers compensation			2,178				2,908				3,801
	Stock based compensation			501				134				1,676
	Permanent items and other			(1,080	)			2,111				2,039
	Domestic manufacturing deduction			767				(1,262	)			—
	Tax differential on foreign earnings			1,123				382				—
	Change in tax rate			(283	)			338				—
	Valuation allowance			36,734				(44,519	)			(25,087	)

	Income tax provision (benefit)		$	25,498			$	(14,271	)		$	3,704

	The American Taxpayer Relief Act of 2012, which reinstated the U.S. federal research and development tax credit retroactively from January 1, 2012 through December 31, 2013, was not enacted into law until the first quarter of 2013. The tax benefit resulting from such reinstatement is reflected in our 2013 tax provision.

	Significant components of our deferred tax assets as of December 31, 2013 and 2012 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the “more-likely-than-not” threshold under GAAP.


			2013				2012
	Deferred tax assets:
	Net operating loss carry forwards		$	46,482			$	45,391
Research credits			8,066				1,848
Stock based compensation			3,486				2,896
Deferred revenue			58				4,596
Development costs			6,495				5,298
Returns and allowances			3,117				7,889
Other, net			5,551				6,021

Total deferred tax assets before valuation allowance			73,255				73,246
Valuation allowance			(49,586	)			(1,818	)

Total deferred tax assets			23,669				72,121
Deferred tax liabilities:
Basis difference in debt			(1,082	)			—
Depreciation and amortization differences			(28,096	)			(36,372	)

Net deferred tax (liability) asset		$	(5,509	)		$	35,749

The increase in the valuation allowance in 2013 was due to uncertainties regarding the realization of deferred tax assets acquired in connection with the Talon acquisition and a change in our overall assessment regarding the realization of our domestic deferred tax assets as a result of larger than expected operating losses sustained in 2013 and an increase in our expected operating loss for 2014. The decrease in the valuation allowance in 2012 was due to a change in our assessment regarding the realization of our domestic deferred tax assets as a result of positive earnings trends in 2010, 2011, and 2012 and operating income recorded in 2011 and 2012.
At December 31, 2013, we had federal and state net operating loss carryforwards of approximately $117.4 million and $132.0 million, respectively. We have approximately $4.1 million of foreign loss carryforwards that will begin to expire in 2028. The federal and state loss carry forwards begin to expire in 2018 and 2014, respectively, unless previously utilized. At December 31, 2013, we had federal and state tax credits of approximately $6.9 million and $2.2 million, respectively. The federal tax credit carryovers begin to expire in 2026 unless previously utilized. The state research and development credits have an indefinite carryover period.
As a result of the prior ownership changes, the utilization of certain net operating loss and research and development tax credit carryforwards including those acquired in connection with the acquisition of Allos and Talon are subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986 and similar state provisions. Any net operating losses or credits that would expire unutilized as a result of Section 382 and 383 limitations have been removed from the table of deferred tax assets and the accompanying disclosures of net operating loss and research and development carryforwards.
Accounting guidance clarifies the accounting for uncertain tax positions and prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, the authoritative guidance addresses the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. Only tax positions that meet the more-likely-than-not recognition threshold at the effective date may be recognized.

The following tabular reconciliation summarizes activity related to unrecognized tax benefits:


		2013				2012				2011
Balance at beginning of year		$	5,482			$	3,928			$	2,803
Adjustments related to prior year tax positions			(200	)			(527	)			5
Increases related to current year tax positions			648				2,515				1,120
Decreases due to settlements			(1,227	)			(434	)			—
Decreases related to prior year tax positions			(2,491	)			—				—

Balance at end of year		$	2,212			$	5,482			$	3,928

During 2013, we continue to believe that our tax positions meet the more-likely-than-not standard required under the recognition phase of the authoritative guidance. However, we consider the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.
Approximately $0.3 million, $5.2 million and $0.2 million of the total unrecognized tax benefits as of December 31, 2013, 2012 and 2011, respectively, would reduce our annual effective tax rate if recognized. Additional amounts in the summary rollforward could impact our effective tax rate if we did not maintain a full valuation allowance on our net deferred tax assets.
We do not expect our unrecognized tax benefits to change significantly over the next 12 months. With a few exceptions, we are no longer subject to U.S. federal, state and local income tax examinations for years before 2009. Our policy is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of operations and are not material.
During 2013, the Internal Revenue Service completed an examination of our 2010 tax return. No tax was paid as a result of the examination. As a result of the examination, the Company reduced tax credits carryovers by $0.8 million and net operating loss carryovers by $1.6 million.

Subsequent_Event

Subsequent Event	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Event	'
	16	SUBSEQUENT EVENT

	BELEODAQ NDA Acceptance by the FDA

	On February 5, 2014, we received a communication from the FDA notifying us that our NDA for BELEODAQ (Belinostat) for Injection had been accepted for filing with priority review. As a result of this achievement, pursuant to the TopoTarget agreement (see Note 14(b)(x)), we paid TopoTarget $10.0 million and issued an aggregate 1.0 million shares of our common stock in February 2014.

Summary_of_Selected_Quarterly_

Summary of Selected Quarterly Financial Data	12 Months Ended
Summary of Selected Quarterly Financial Data	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Selected Quarterly Financial Data	'
	17	SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
	Selected quarterly financial data (unaudited) for the year ended December 31, 2013 and 2012 is presented below:


			Quarter Ended (Unaudited)
			March 31			June 30			September 30			December 31
	2013:00:00
	Total revenues		$	38,667		$	33,232		$	42,439		$	41,516
	Operating loss		$	(6,457	)	$	(12,529	)	$	(13,287	)	$	(6,512	)
	Net loss		$	(5,435	)	$	(9,721	)	$	(7,812	)	$	(39,166	)
	Net loss per share, basic		$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)
	Net loss per share, diluted		$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)
	2012:00:00
	Total revenues		$	59,859		$	68,702		$	69,042		$	70,104
	Operating income		$	23,596		$	23,028		$	23,109		$	11,041
	Net income		$	46,838		$	18,350		$	21,524		$	7,489
	Net income per share, basic		$	0.8		$	0.31		$	0.37		$	0.13
	Net income per share, diluted		$	0.72		$	0.29		$	0.33		$	0.12
	Net (loss) income per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the year.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]	'
Schedule II - Valuation and Qualifying Accounts	'

	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS

	Years Ended December 31, 2013, 2012, and 2011



	Description		Balance at		Additions					Deductions (1)			Balance at
			Beginning of		(Reductions)								End of
			Period		Additions			Charged					Period
					(Recovery)			to Other
					to Bad Debt			Accounts
					Expense or
					Deferred
					Tax Asset
			(in thousands)
	Year ended December 31, 2013
	Allowance for doubtful accounts		$	228	$	11			—	$	(33	)	$	206
	Year ended December 31, 2012
	Allowance for doubtful accounts		$	471	$	(128	)		—	$	(115	)	$	228
	Year ended December 31, 2011
	Allowance for doubtful accounts		$	339	$	139			—	$	(7	)	$	471


	-1	Deductions represent the actual write-off of accounts receivable balances.

Description_of_Business_Basis_1

Description of Business, Basis of Presentation, and Operating Segment (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Description of Business	'
	(a) Description of Business
	Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (“Spectrum”, the “Company”, “we”, “our”, or “us”), is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products.
	We currently market four drugs:

		•		FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

		•		ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma;

		•		FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and

		•		MARQIBO injection for patients in the U.S. with Philadelphia chromosome–negative acute lymphoblastic leukemia.
	We also have a pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research, regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.
Basis of Presentation	'
	(b) Basis of Presentation
	Principles of Consolidation
	The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.
	On April 1, 2012, we acquired the licensing rights outside of the U.S. to market ZEVALIN (the “ZEVALIN Rights”); on September 5, 2012, we acquired Allos Therapeutics, Inc. (“Allos”); and on July 17, 2013, we acquired Talon Therapeutics, Inc. (“Talon”). Our accompanying Consolidated Financial Statements include the assets acquired and liabilities assumed in connection with these acquisitions, in addition to the operating results and cash flows, beginning with the corresponding acquisition date for each acquisition.
	Variable Interest Entity
	We own fifty-percent of Spectrum Pharma Canada (a “variable interest entity,” as defined under applicable GAAP), which was organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this entity. We are obligated to fund all costs of this entity and have the sole rights to any revenue derived from its operations. Since we carry the full risks and rewards of this entity, we meet the applicable GAAP criteria as its “primary beneficiary”. As the primary beneficiary of this variable interest entity, Spectrum Pharma Canada’s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.
Operating Segment	'
	(c) Operating Segment
	We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December 31, 2013, 2012, and 2011, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our long-lived assets are located in the U.S.
Revenue Recognition	'
	(i) Revenue Recognition
	(a) Product Sales: We sell our products to wholesalers and distributors. Our wholesalers and distributors purchase our products and sell the products directly to end-users, such as clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized upon shipment of product when title and risk of loss have transferred to our customer, and the following additional criteria are met:

		-1	appropriate evidence of a binding arrangement exists with our customer;

		-2	price is substantially fixed and determinable;

		-3	collection from our customer is reasonably assured;

		-4	our customer’s obligation to pay us is not contingent on resale of the product;

		-5	we do not have significant obligations for future performance to directly bring about the resale of our product; and

		-6	we have a reasonable basis to estimate returns.
	Our gross revenue is reduced by our gross-to-net (“GTN”) estimates, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.
	Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:
	Product Returns Allowances: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.
	Government Chargebacks: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.
	Discounts: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.
	Rebates: Rebates are estimated based on the customer’s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.

	Medicaid Rebates: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management’s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.
	Distribution and Data Fees: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.
	(b) License Fees: We recognize license fees based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum license fee in which revenue is recognized in that period.
	(c) Service Revenue: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.
Cash and Equivalents	'
	(ii) Cash and Equivalents
	Cash and equivalents consist of highly liquid investments with original maturities of three months or less from the original purchase date.
Marketable Securities	'
	(iii) Marketable Securities
	Marketable securities are equity securities. These are classified as available-for-sale, with any unrealized change in value reflected in “unrealized gain (loss) on securities” on the accompanying Consolidated Statements of Comprehensive Income (Loss).
Accounts Receivable	'

	(iv) Accounts Receivable

	Accounts receivable are recorded at the invoiced amount, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.
Inventories	'
	(v) Inventories
	We value inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory (i.e., net realizable value). Cost is determined on the first-in, first-out method (FIFO). We regularly review inventory quantities in process and on hand, and when appropriate, record a provision for obsolete and excess inventory to reduce it to its net realizable value.
Prooperty and Equipment	'

	(vi) Property and Equipment

	Property and equipment are stated at cost and depreciated on a straight-line basis over its estimated useful lives. In the case of leasehold improvements, depreciation is over the shorter of the estimated useful life or remaining term of the lease. We evaluate the recoverability of long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.
Goodwill and Intangible Assets	'
	(vii) Goodwill and Intangible Assets
	Goodwill represents the excess of acquisition cost over the fair value of the net assets of the acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually unless there are interim impairment indicators. We perform our annual evaluation as of October 1 each year.
	We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:

		(a)	a significant decrease in the market value of an asset;

		(b)	a significant adverse change in the extent or manner in which an asset is used; or

		(c)	an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.
Stock-Based Compensation	'
	(viii) Stock-Based Compensation
	We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.
	We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.
Foreign Currency Translation	'
	(ix) Foreign Currency Translation
	We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using rates of exchange in effect during the period. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of comprehensive income (loss).
	We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any period presented.
Comprehensive Income (Loss)	'
	(x) Comprehensive Income (Loss)
	Comprehensive income (loss) is calculated in accordance with authoritative guidance which requires the disclosure of all components of comprehensive income, including net income (loss) and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources.
Basic and Diluted Net Income (Loss) per Share	'

	(xi) Basic and Diluted Net (Loss) Income per Share

	We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.
Income Taxes	'
	(xii) Income Taxes
	Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.
	We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance of our deferred tax assets would increase net income in the period such determination was made. In the event that we were assessed interest and/or penalties from taxing authorities, such amounts would be included in “income tax expense” within the Consolidated Statements of Operations and Comprehensive Income (Loss) in the period the notice was received.
Research and Development Costs	'
	(xiii) Research and Development Costs
	Research and development costs are expensed as incurred.
Fair Value Measurements	'
	(xiv) Fair Value Measurements
	We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
	Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	“Cash and equivalents” within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. “Marketable securities” consist of publicly-traded equity instruments that are valued utilizing Level 1 inputs.
	The fair value of our “drug development liability” and our “deferred payment contingency” within our accompanying Consolidated Balance Sheets was valued using a model commonly referred to as the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i) internal estimates of research and development personnel costs needed to perform the research and development services, (ii) estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.
	“Acquisition-related contingent obligations” within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with various business combinations. See Note 10(a) for a discussion of CVRs granted as part of our acquisition of Talon, and Note 10(b) for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.

Balance_Sheet_Account_Detail_T

Balance Sheet Account Detail (Tables)	12 Months Ended
Balance Sheet Account Detail (Tables)	Dec. 31, 2013
Text Block [Abstract]	'
Summary of Cash and Equivalents and Marketable Securities	'

	The following is a summary of our cash and equivalents and marketable securities:



			Cost			Gross			Gross			Estimated			Cash and		Marketable Securities
						Unrealized			Unrealized			fair			equivalents		Marketable Securities
						Gains			Losses			Value					Current		Long
																	Current		Term
	December 31, 2013
	Bank deposits		$	55,911		$	—		$	—		$	55,911		$	55,911	$	—	$	—
	Money market funds			100,395									100,395			100,395
	Bank CDs			410			—			—			410			—		410		—
	Mutual funds			3,061			—			—			3,061			—		3,061		—

	Total cash and equivalents and marketable securities		$	159,777		$	—		$	—		$	159,777		$	156,306	$	3,471	$	—

	December 31, 2012
	Bank deposits		$	128,000		$	—		$	—		$	128,000		$	128,000	$	—	$	—
	Money market funds			11,698									11,698			11,698
	Bank CDs			987			—			—			987			—		987		—
	Mutual funds			2,323			—			—			2,323			—		2,323		—

	Total cash and equivalents and marketable securities		$	143,008		$	—		$	—		$	143,008		$	139,698	$	3,310	$	—

Schedule of Property and Equipment	'
	Property and equipment consist of the following:


			December 31,
			2013			2012
	Computers and software		$	5,154		$	4,540
	Lab and media equipment			1,063			886
	Office furniture and equipment			1,575			1,492
	Leasehold improvements			2,813			2,799
	Assets held under capital lease obligations			—			146

	Property and equipment, at cost			10,605			9,863
	(Less): accumulated depreciation and amortization			(9,070	)		(7,315	)

	Property and equipment, net		$	1,535		$	2,548

Components of Inventories, Net	'
	Inventories, net consist of the following:


			December 31,
			2013			2012
	Raw materials		$	1,794		$	887
	Work in process			3,312			7,302
	Finished goods			8,413			6,289

	Inventories		$	13,519		$	14,478

Components of Intangible Assets	'
	Intangible assets consist of the following:


						December 31, 2013
			Historical			Accumulated			Foreign			Impairment			Net Amount		Full		Remaining
			Cost			Amortization			Currency								Amortization		Amortization
									Translation								Period (years)		Period (years)
	MARQIBO IPR&D		$	17,600		$	—		$	—		$	—		$	17,600		n/a		n/a
	MELPHALAN IPR&D			7,700			—			—			—			7,700		n/a		n/a
	MARQIBO developed technology			26,900			(1,107	)		—			—			25,793		11		11
	ZEVALIN marketing rights – U.S.			41,900			(23,455	)		—			—			18,445		10		5
	ZEVALIN marketing rights – Ex-U.S.			23,490			(5,343	)		682			—			18,829		8		6
	FUSILEV developed technology			16,778			(4,821	)		—			—			11,957		11		8
	FOLOTYN distribution rights*			27,900			(3,662	)		—			(1,023	)		23,215		10		9
	FOLOTYN developed technology			118,400			(10,587	)		—			—			107,813		13		12

	Total intangible assets		$	280,668		$	(48,975	)	$	682		$	(1,023	)	$	231,352


	*	On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., the FOLOTYN distribution rights). We determined that an impairment of the FOLOTYN distribution rights of $1.0 million resulted from the amendment and is recorded in the “amortization and impairment of intangible assets” in the accompanying Consolidated Statement of Operations for the year ended December 31, 2013.


			December 31, 2012
			Historical			Accumulated			Foreign			Net
			Cost			Amortization			Currency			Amount
									Translation
	ZEVALIN marketing rights – U.S.		$	41,900		$	(19,735	)	$	—		$	22,165
	ZEVALIN marketing rights – Ex-U.S.			23,490			(2,192	)		(355	)		20,943
	FUSILEV developed technology			16,778			(2,980	)		—			13,798
	FOLOTYN distribution rights			27,900			(895	)		—			27,005
	FOLOTYN developed technology			118,400			(2,077	)		—			116,323

	Total intangible assets		$	228,468		$	(27,879	)	$	(355	)	$	200,234

Estimated Intangible Asset Amortization Expense	'

	Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:



	Years Ending December 31
	2014		$	22,468
	2015			22,468
	2016			22,468
	2017			22,468
	2018			22,313
	2019 and thereafter			93,867

			$	206,052

Schedule of Goodwill	'
	Goodwill is comprised of the following (by source):


			December 31,			December 31,
			2013			2012
	Acquisition of Talon		$	10,526			—
	Acquisition of ZEVALIN Rights			2,525		$	2,525
	Acquisition of Allos			5,346			4,791
	Foreign exchange translation effects			104			(37	)

			$	18,501		$	7,279

Summaey of Other Assets	'
	Other assets are comprised of the following:


			December 31,			December 31,
			2013			2012
	Investments in equity securities		$	3,593		$	2,476
	Deposits			190			304
	Debt issuance cost			3,432			814
	Life insurance cash surrender value			5,361			2,881

			$	12,576		$	6,475

Schedule of Accounts Payable and Other Accrued Obligations	'

	Accounts payable and other accrued obligations are comprised of the following:



			December 31,
			2013			2012
	Trade payables		$	12,796		$	30,814
	Accrued rebates			28,893			11,023
	Accrued product royalty			9,498			12,275
	Allowance for returns			2,900			5,056
	Accrued data and distribution fees			2,430			8,449
	Accrued GPO administrative fees			2,327			2,650
	Inventory management fee			616			3,050
	Accrued income taxes			3			2,522
	Allowance for chargebacks			5,074			15,153
	Accrued drug development costs			6,433			11,441
	Other accrued obligations			8,867			2,819

			$	79,837		$	105,252

Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations	'

	Amounts presented within “accounts payable and other accrued obligations” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:



	Description		Rebates and			Data and			Prompt			Returns
			Chargebacks			Distribution,			Pay
						GPO Fees, and			Discount
						Inventory
						Management
						Fees

	Balance as of December 31, 2011		$	9,064		$	9,808		$	992		$	4,000
	Allos accruals assumed			2,371			182			—			941
	Add: provisions (recovery)			91,059			32,793			4,814			159
	Less: credits or actual allowances			(76,318	)		(28,634	)		(4,355	)		(44	)

	Balance as of December 31, 2012			26,176			14,149			1,451			5,056
	Add: provisions (recovery)			63,609			19,067			183			(2,034	)
	Less: credits or actual allowances			(55,818	)		(27,843	)		(1,317	)		(122	)

	Balance as of December 31, 2013		$	33,967		$	5,373		$	317		$	2,900

Summary of Other Long-Term Liabilities	'

	Other long-term liabilities are comprised of the following:



			December 31,
			2013			2012
	Accrued executive deferred compensation		$	3,949		$	2,366
	Deferred rent (non-current portion)			366			571
	Business acquisition liability			298			298
	Other tax liabilities			1,352			1,132

			$	5,965		$	4,367

Grossto_Net_Product_Sales_Tabl

Gross-to Net Product Sales (Tables)	12 Months Ended
Gross-to Net Product Sales (Tables)	Dec. 31, 2013
Text Block [Abstract]	'
Reconciliation of Gross to Net Product Sales	'
	The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:


		2013			2012			2011
	Gross product sales	$	224,301		$	383,817		$	220,670
	Rebates and government chargebacks		(63,610	)		(91,059	)		(22,190	)
	Distribution and data fees and group purchasing organizations fees		(19,067	)		(32,793	)		(11,637	)
	Prompt pay discounts		(183	)		(4,814	)		(4,086	)
	Product returns allowance		2,034			(159	)		(2,094	)

	Product sales, net	$	143,475		$	254,992		$	180,663

Product_Sales_Net_by_Geographi1

Product Sales, Net by Geographic Region and Product Line (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Schedule of Product Sales, Net by Geography	'
	The below table presents product sales, net by geography for the years ended December 31, 2013, 2012, and 2011:


		Year Ended December 31,
		2013				2012				2011
	United States	$	133,462	93	%	$	245,697	96.4	%	$	180,663	—	%

	International:
	Europe		3,953	2.8	%		3,113	1.2	%		—	—	%
	Asia Pacific		6,060	4.2	%		6,182	2.4	%		—	—	%

	Total International		10,013	7	%		9,295	3.6	%		—	—	%

	Product sales, net	$	143,475	100	%	$	254,992	100	%	$	180,663	100	%

Schedule of Product Sales, Net by Product Line	'
	The below table presents product sales, net by product line for the years ended December 31, 2013, 2012, and 2011:


		Year Ended December 31,
		2013				2012				2011
	FUSILEV	$	68,397	47.7	%	$	204,253	80.1	%	$	153,110	84.7	%
	FOLOTYN		44,370	30.9	%		20,412	8	%		—	—	%
	ZEVALIN		29,393	20.5	%		30,327	11.9	%		27,553
	MARQIBO		1,315	0.9	%		—	—	%		—	—	%

	Product sales, net	$	143,475	100	%	$	254,992	100	%	$	180,663	15.3	%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2013
Summary of Stock-Based Compensation Expense	'
	Stock-based compensation expense included within operating expenses for years ended December 31, 2013, 2012, and 2011 was as follows:


			Year Ended December 31,
			2013			2012		2011
	Selling, general and administrative		$	10,762		$	13,041	$	20,609
	Research and development			2,017			1,843		1,628

	Total		$	12,779		$	14,884	$	22,237

Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model	'
	The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:


			Year Ended December 31,
			2013		2012	2011
	Expected option life (in years) (a)		4.95		4.5	4.93
	Risk-free interest rate (b)		0.35% - 0.78%		0.34% - 0.51%	0.82% - 2.4%
	Volatility (c)		58.3% - 71.5%		64.2% -73.6%	55.80%
	Dividend yield (d)		0%		0%	0%
	Weighted-average grant-date fair value per stock option		$4.66		$6.20	$2.65

	(a)	Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).
	(b)	Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options’ expected term).
	(c)	Measured using our historical stock price for a period equal to stock options’ expected term.
	(d)	We do not expect to declare any cash dividends in the foreseeable future.
Summary of Stock Option Activity	'

	Stock option activity during the years ended December 31, 2013, 2012, and 2011 is as follows:



			Number of			Weighted-		Weighted-		Aggregate
			Shares			Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price/Share		Contractual
								Term (Years)
	Outstanding — December 31, 2010			8,397,094		$	4.17
	Granted			3,622,150			7.92
	Exercised			(1,126,257	)		4.07			$	8,255	(1)
	Forfeited			(547,479	)		4.81
	Expired			(159,987	)		5.17

	Outstanding — December 31, 2011			10,185,521		$	5.46
	Granted			1,821,915			11.57
	Exercised			(1,287,430	)		4.52			$	11,500	(1)
	Forfeited			(316,825	)		7.93
	Expired			(3,916	)		7.69

	Outstanding — December 31, 2012			10,399,265		$	6.57
	Granted			2,041,300			8.92
	Exercised			(825,884	)		4.4			$	3,435	(1)
	Forfeited			(202,882	)		8.22
	Expired			(82,581	)		8.91

	Outstanding — December 31, 2013			11,329,218		$	7.1		7	$	25,849	(2)

	Vested (exercisable) — December 31, 2013			7,876,025		$	6.11		6.2	$	24,080	(2)

	Unvested (unexercisable) — December 31, 2013			3,453,193		$	9.38		8.9	$	1,770	(2)



	-1	Represents the total difference between our closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
	-2	Represents the total difference between our closing stock price on the last trading day of 2013 and the stock option exercise price, multiplied by the number of in-the-money options as of December 31, 2013. The amount of intrinsic value will change based on the fair market value of our stock.
Summary of Stock Option Grants	'

	The following table summarizes information with respect to stock option grants as of December 31, 2013:



			Outstanding							Exercisable
	Exercise Price		Granted Stock			Weighted-		Weighted-		Granted			Weighted-
			Options			Average		Average		Stock			Average
			Outstanding			Remaining		Exercise		Options			Exercise
						Contractual		Price		Exercisable			Price
						Life (Years)
	$0.92 – 3.15			1,192,794			4.5	$	2.16		1,192,794		$	2.16
	$3.55 – 4.95			1,924,904			5.9		4.23		1,865,794			4.23
	$5.05 – 6.90			2,862,699			5.5		6.26		2,565,220			6.19
	$7.00 – 8.99			2,329,167			8.2		8.17		1,147,138			8.26
	$9.00 – 16.32			3,019,654			9.2		10.86		1,105,079			11.09

				11,329,218			7	$	7.1		7,876,025		$	6.11

Summary of Restricted Stock Activity	'

	A summary of restricted stock activity is as follows:



			Number of			Weighted Average
			Restricted Stock			Fair Value per
			Awards			Share at Grant
						Date
	Unvested as of December 31, 2010			359,500		$	3.96
	Granted			1,781,000			12.48
	Vested			(1,104,025	)		12.33
	Forfeited			(83,950	)		4.78

	Unvested — December 31, 2011			952,525			10.11
	Granted			586,639			11.76
	Vested			(472,160	)		10.26
	Forfeited			(32,400	)		9.57

	Unvested — December 31, 2012			1,034,604			11
	Granted			523,800			8.74
	Vested			(501,660	)		9.72
	Forfeited			(49,625	)		10.6

	Unvested — December 31, 2013			1,007,119		$	10.09



	*	Represents our stock price on the vesting date multiplied by the number of vested shares.


Issued Shares of Common Stock	'
	We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employee contributions, as summarized below:


			2013			2012		2011
	Shares of common stock issued			99,359			56,254		65,889
	Match contribution value**		$	860		$	691	$	593

	**	Represents our stock price on the date of the stock match multiplied by the number of shares of common stock issued.
Restricted stock awards [Member]	'
Fair Value of Restricted Stock Awards	'

			2013			2012		2011
	Restricted stock expense		$	4,202		$	6,500	$	4,100

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2013
Equity [Abstract]	'
Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted	'
	As of December 31, 2013, approximately 28.1 million shares of our common stock were issuable upon conversion or exercise of rights granted, or to be granted, as summarized below:


	Conversion of Series E Preferred Stock		40,000
	2018 Convertible Notes		11,400,000
	Exercise of issued employee stock options		11,329,218
	Exercise of issued warrants		445,000
	ESPP shares reserved		4,540,986
	Long-term retention and management incentive plan shares		346,500

	Total shares of common stock reserved for future issuances		28,101,704

Summary of Warrant Activity	'
	A summary of warrant activity is as follows:


		Number of			Weighted
		Shares			Average
					Exercise Price
	Outstanding — December 31, 2010		4,192,312		$	6.45
	Expired		(3,747,312	)		6.62

	Outstanding — December 31, 2011		445,000		$	5.04
	Exercised		(50,000	)		1.79

	Outstanding — December 31, 2012		395,000		$	5.45
	Granted		50,000			7.51

	Outstanding — December 31, 2013		445,000		$	6.39

	Exercisable — December 31, 2013		407,500		$	6.29

Net_Loss_Income_Per_Share_Tabl

Net (Loss) Income Per Share (Tables)	12 Months Ended
Net (Loss) Income Per Share (Tables)	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Computation of Net (Loss) Income Per Share	'

	Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December 31, 2013, 2012, and 2011:



		Year Ended December 31,
		2013			2012		2011
	Net (loss) income	$	(62,134	)	$	94,201	$	49,931

	Weighted average shares - basic		60,729,128			58,588,916		53,272,767
	Net (loss) income per share - basic	$	(1.02	)	$	1.61	$	0.94

	Weighted average shares - diluted		60,729,128			64,637,256		57,959,714
	Net (loss) income per share - diluted	$	(1.02	)	$	1.46	$	0.86
Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share	'
	The following summarizes the amounts used in computing basic and diluted net income per share, for the years ended 2012 and 2011:


		Net Income			Weighted-		Net
		(numerator)			Average		Income
					Shares		Per Share
					Outstanding
					(Denominator)
	Year Ended December 31, 2012
	Basic net income per share:	$	94,201			58,588,916	$	1.61

	Diluted net income per share:
	Dilutive preferred shares					40,000
	Dilutive common stock options					4,749,299
	Incremental common stock assumed issued on exercise of in-the-money warrants					224,437
	Unvested restrictive stock awards					1,034,604

	Diluted net income per share	$	94,201			64,637,256	$	1.46



		Net Income			Weighted-		Net
		(numerator)			Average		Income
					Shares		Per Share
					Outstanding
					(Denominator)
	Year Ended December 31, 2011
	Basic net income per share:	$	49,931			53,272,767	$	0.94

	Diluted net income per share:
	Dilutive preferred shares					40,000
	Dilutive common stock options					4,185,224
	Change in common stock related to Targent and management incentive plan milestones, as if they had been issued at the beginning of the quarter earned					248,193
	Incremental common stock assumed issued on exercise of in-the-money warrants					200,656
	Unvested restrictive stock awards					12,874

	Diluted net income per share	$	49,931			57,959,714	$	0.86

Schedule of Securities Excluded from Calculation of Net (Loss) per Share	'
	Our outstanding securities were excluded from the above calculation of net (loss) per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net (loss) per share in 2013:


		Year Ended December 31,
		2013			2012		2011
	2018 Convertible Notes		343,600			—		—
	Common stock options		2,934,625			—		—
	Restricted stock awards		1,007,119			—		—
	Common stock warrants		160,816			—		—
	Preferred stock		40,000			—		—

	Total		4,486,160			—		—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Summary of Asset and Liability Fair Values	'

	The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories (as described within Note 2 (x)):



		December 31, 2013
		Fair Value Measurements
		Level 1			Level 2		Level 3		Total

	Assets:
	Bank CDs	$	—		$	410	$	—	$	410
	Money market currency funds		—			100,395		—		100,395
	Mutual funds		—			3,061		—		3,061
	Deferred compensation investments, including life insurance cash surrender value		—			5,361		—		5,361
	Equity securities		3,593			—		—		3,593

		$	3,593		$	109,227	$	—	$	112,820

	Liabilities:
	Deferred executive compensation liability		—			3,949		—		3,949
	Deferred development costs		—			—		17,742		17,742
	Ligand Contingent Consideration		—			—		4,000		4,000
	Talon CVR		—			—		4,329		4,329

		$	—		$	3,949	$	26,071	$	30,020




		December 31, 2012
		Fair Value Measurements
		Level 1			Level 2		Level 3		Total

	Assets:
	Bank CDs	$	—		$	987	$	—	$	987
	Money market currency funds					11,698		—		11,698
	Mutual funds		—			2,323		—		2,323
	Deferred compensation investments, including life insurance cash surrender value		—			2,881		—		2,881
	Equity securities		2,480			—		—		2,480

		$	2,480		$	17,889	$	—	$	20,369

	Liabilities:
	Deferred executive compensation liability		—			2,365		—		2,365
	Deferred development costs		—			—		12,233		12,233
	Deferred payment contingency		—			—		2,287		2,287
	Ligand Contingent Consideration		—			—		—		—

		$	—		$	2,365	$	14,520	$	16,885

Activity of Level 3 Inputs Measured on Recurring Basis	'

	The following presents a roll forward of our liabilities for which we utilize Level 3 inputs (see Note 2(x)) in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “accrued and deferred development costs, less current portion”. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.



		Fair Value Measurements of
		Unobservable Inputs (Level 3)
	Balance at December 31, 2011	$	—
	Transfers in (out)		—
	Deferred development costs		12,233
	Deferred payment contingency		2,287

	Balance at December 31, 2012		14,520
	Transfers in (out)		—
	Deferred development costs (see Note 13)		5,509
	Deferred payment contingency (see Note 13)		(2,287	)
	Ligand Contingent Consideration (see Note 10(b))		4,000
	Talon CVR (see Note 10(a))		4,329

	Balance at December 31, 2013	$	26,071

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
Business Combinations (Tables)	Dec. 31, 2013
Acquisition-Date Fair Value of Consideration Transferred	'
	The Talon acquisition purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based upon their estimated fair value at the acquisition date. The following table summarizes the purchase price:


	Cash consideration		$	11,300
	CVR			6,500
	Spectrum shares of common stock			26,300

	Total purchase consideration		$	44,100

Supplemental Pro Forma Financial Information	'

	The following unaudited pro forma financial information is presented to reflect the results of the Company’s consolidated operations for the years ended December 31, 2013 and 2012, as if the acquisition of Talon had occurred on January 1, 2012. To reflect the combined businesses, adjustments have been made to exclude one-time transaction costs and employee severance costs that were directly associated with the Talon acquisition. These pro forma results have been prepared for informational purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January 1, 2012, and may not be indicative of future operating results.



			Year Ended December 31,
			2013			2012
	Pro Forma Total revenues		$	155,854		$	267,707
	Pro Forma Total costs and operating expenses			200,651			210,433
	Pro Forma Net (loss) income			(68,146	)		57,274
	Pro Forma Net (loss) income per share – basic		$	(1.12	)	$	0.98
	Pro Forma Net (loss) income per share – diluted		$	(1.12	)	$	0.89
Amortization Period for such Intangible Assets Acquired	'

	The acquired intangible assets consisted of developed technology and in-process research and development (“IPR&D”) for MARQIBO treatment of acute lymphoblastic leukemia (“ALL”) and MARQIBO treatment of non-Hodgkin’s lymphoma (“NHL”) as follows in the table below:



			Value of			Amortization
			Intangible			Period*
			Assets
			Acquired
	Developed technology —MARQIBO for ALL		$	26,900			13 years
	IPR&D —MARQIBO for NHL			17,600				-1

	Total identifiable intangible assets		$	44,500



	*	Recognized on a straight-line basis.
	-1	IPR&D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&D is not amortized during this period, but rather tested for impairment.
Summary of Allocation of Total Purchase Price to Net Assets Acquired	'

	The following table summarizes the estimated fair value of the net assets acquired on July 17, 2013:



	Cash and equivalents		$	131
	Inventory			611
	Prepaid expenses and other current assets			109
	Property and equipment			30
	Identifiable intangible assets			44,500


	Total assets acquired			45,381


	Accounts payable & accrued liabilities			5,231
	Deferred tax liability			6,576


	Total liabilities assumed			11,807

	Net assets acquired		$	33,574



	Goodwill		$	10,526

Talon Therapeutics, Inc. [Member]	'
Acquisition-Date Fair Value of Consideration Transferred	'
	The acquisition-date fair value of the consideration transferred consisted of the following items:


	Cash consideration		$	3,000
	Ligand Contingent Consideration			4,700

	Total purchase consideration		$	7,700

Change in Fair Value of Contingent Consideration Related to Acquisition	'
	Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.


			Fair Value
			of Talon
			CVR
	July 17, 2013		$	6,500
	Fair value adjustment for year ended December 31, 2013			(2,171	)

	December 31, 2013		$	4,329


Melphalan license [Member]	'
Change in Fair Value of Contingent Consideration Related to Acquisition	'

	Adjustments to Ligand Contingent Consideration fair value are recognized within “fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.



			Fair Value of
			Ligand
			Contingent
			Consideration
	March 8, 2013		$	4,700
	Fair value adjustment for year ended December 31, 2013			(700	)

	December 31, 2013		$	4,000

Summary of Allocation of Total Purchase Price to Net Assets Acquired	'

	The allocation of the total purchase price to the net assets acquired is as follows:



	IPR&D—C-E MELPHALAN rights		$	7,700

Convertible_Senior_Notes_Table

Convertible Senior Notes (Tables)	12 Months Ended
Convertible Senior Notes (Tables)	Dec. 31, 2013
Text Block [Abstract]	'
Carrying Values of 2018 Convertible Notes	'
	The carrying values of the 2018 Convertible Notes as of December 31, 2013 is summarized as follows:


	Principal amount	$	120,000
	(Less): Unamortized debt discount (amortized through December 2018)		(28,520	)

	December 31, 2013 net carrying amount of 2018 Convertible Notes	$	91,480

Components of Total Interest Expense Recognized	'
	The following table sets forth the components of total “interest expense” recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the year ended December 31, 2013:


	Contractual coupon interest expense	$	73
	Amortization of debt issuance costs		43
	Accretion of debt discount		101

	Total	$	217

	Effective interest rate		8.59	%

Mundipharma_Agreement_Tables

Mundipharma Agreement (Tables)	12 Months Ended
Mundipharma Agreement (Tables)	Dec. 31, 2013
Text Block [Abstract]	'
Schedule of Drug Development Liability Adjustments	'

	We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our Consolidated Statements of Operations.



		Year Ended December 31,
		Drug			Drug			Total Drug
		Development			Development			Development
		Liability,			Liability,			Liability –
		Current –			Long Term –			FOLOTYN
		FOLOTYN			FOLOTYN
	Balance at December 31, 2012	$	856		$	11,377		$	12,233
	Transfer from long term to current		3,620			(3,620	)		—
	Amended agreement payment receipt		—			7,000			7,000
	(Less): Expenses incurred		(1,357	)		(134	)		(1,491	)

	Balance at December 31, 2013	$	3,119		$	14,623		$	17,742

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Lease Payments	'

	Our future minimum lease payments are as follows:



	Year ending December 31,	Operating Lease
		Minimum
		Payments
	2014	$	849
	2015		950
	2016		892
	2017		843
	2018		868

		$	4,402

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of (Loss) Income before (Provision) Benefit for Income Taxes	'

	The components of (loss) income before (provision) benefit for income taxes are as follows:



		For the Years Ended
		December 31,
		2013			2012			2011

	United States	$	(30,437	)	$	82,165		$	53,834
	Foreign		(6,199	)		(2,235	)		(199	)

	Total	$	(36,636	)	$	79,930		$	53,635



Provision (Benefit) for Income Taxes	'
	The provision (benefit) for income taxes consist of the following:


		For the Years Ended
		December 31,
		2013			2012			2011
	Current:
	Federal	$	(8,357	)	$	16,222		$	1,255
	State		(691	)		3,412			2,449
	Foreign		—			—			—

		$	(9,048	)	$	19,634		$	3,704
	Deferred:
	Federal		36,183			(24,013	)		—
	State		(1,637	)		(9,892	)		—
	Foreign		—			—			—

			34,546			(33,905	)		—
	Total income tax provision (benefit)	$	25,498		$	(14,271	)	$	3,704

Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes	'

	The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:



		2013			2012			2011
	Tax provision (benefit) computed at the federal statutory rate	$	(12,822	)	$	27,975		$	18,250
	State tax, net of federal benefit		(246	)		2,442			2,918
	Expired tax attributes		—			—			385
	Research credits		(2,254	)		(2,129	)		(1,464	)
	Benefits from credit study		—			(4,148	)		—
	Common stock warrant liability		—			—			1,186
	Transaction costs		880			1,497			—
	Officers compensation		2,178			2,908			3,801
	Stock based compensation		501			134			1,676
	Permanent items and other		(1,080	)		2,111			2,039
	Domestic manufacturing deduction		767			(1,262	)		—
	Tax differential on foreign earnings		1,123			382			—
	Change in tax rate		(283	)		338			—
	Valuation allowance		36,734			(44,519	)		(25,087	)

	Income tax provision (benefit)	$	25,498		$	(14,271	)	$	3,704

Components of Company's Deferred Tax Assets	'

	Significant components of our deferred tax assets as of December 31, 2013 and 2012 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the “more-likely-than-not” threshold under GAAP.



		2013			2012
	Deferred tax assets:
	Net operating loss carry forwards	$	46,482		$	45,391
	Research credits		8,066			1,848
	Stock based compensation		3,486			2,896
	Deferred revenue		58			4,596
	Development costs		6,495			5,298
	Returns and allowances		3,117			7,889
	Other, net		5,551			6,021

	Total deferred tax assets before valuation allowance		73,255			73,246
	Valuation allowance		(49,586	)		(1,818	)

	Total deferred tax assets		23,669			72,121
	Deferred tax liabilities:
	Basis difference in debt		(1,082	)		—
	Depreciation and amortization differences		(28,096	)		(36,372	)

	Net deferred tax (liability) asset	$	(5,509	)	$	35,749

Summary of Unrecognized Tax Benefits	'

	The following tabular reconciliation summarizes activity related to unrecognized tax benefits:



		2013			2012			2011
	Balance at beginning of year	$	5,482		$	3,928		$	2,803
	Adjustments related to prior year tax positions		(200	)		(527	)		5
	Increases related to current year tax positions		648			2,515			1,120
	Decreases due to settlements		(1,227	)		(434	)		—
	Decreases related to prior year tax positions		(2,491	)		—			—

	Balance at end of year	$	2,212		$	5,482		$	3,928

Summary_of_Selected_Quarterly_1

Summary of Selected Quarterly Financial Data (Tables)	12 Months Ended
Summary of Selected Quarterly Financial Data (Tables)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Selected Quarterly Financial Data	'
	Selected quarterly financial data (unaudited) for the year ended December 31, 2013 and 2012 is presented below:


		Quarter Ended (Unaudited)
		March 31			June 30			September 30			December 31
	2013:00:00
	Total revenues	$	38,667		$	33,232		$	42,439		$	41,516
	Operating loss	$	(6,457	)	$	(12,529	)	$	(13,287	)	$	(6,512	)
	Net loss	$	(5,435	)	$	(9,721	)	$	(7,812	)	$	(39,166	)
	Net loss per share, basic	$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)
	Net loss per share, diluted	$	(0.09	)	$	(0.16	)	$	(0.13	)	$	(0.63	)
	2012:00:00
	Total revenues	$	59,859		$	68,702		$	69,042		$	70,104
	Operating income	$	23,596		$	23,028		$	23,109		$	11,041
	Net income	$	46,838		$	18,350		$	21,524		$	7,489
	Net income per share, basic	$	0.8		$	0.31		$	0.37		$	0.13
	Net income per share, diluted	$	0.72		$	0.29		$	0.33		$	0.12

Description_of_Business_Basis_2

Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Segment
Segment Reporting Information [Line Items]	'
Number of reportable operating segment	1
ZEVALIN [Member]	'
Segment Reporting Information [Line Items]	'
Acquisition date	1-Apr-12
Allos Therapeutics, Inc. [Member]	'
Segment Reporting Information [Line Items]	'
Acquisition date	5-Sep-12
Talon Therapeutics, Inc. [Member]	'
Segment Reporting Information [Line Items]	'
Acquisition date	17-Jul-13
Spectrum Pharma Canada [Member]	'
Segment Reporting Information [Line Items]	'
Ownership interest, percentage	50.00%

Summary_of_Significant_Account1

Summary of Significant Accounting Policies and Use of Estimates - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Regulatory Assets [Abstract]	'
Number of months customers are allowed to return products	'6 months
Cash and equivalents maturities period	'3 months

Balance_Sheet_Account_Detail_A

Balance Sheet Account Detail - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule Of Investments [Abstract]	'	'	'
Cash, equivalents and marketable securities, including long term bank certificates of deposits, and investments, total	$159.80	$143	'
Securities in continuous unrealized loss position, period	'Longer than one year	'	'
Depreciation expense	1.2	1.2	0.9
Intangible asset amortization expense	$21.20	$8.80	$4.70

Balance_Sheet_Account_Detail_S

Balance Sheet Account Detail - Summary of Cash and Equivalents and Marketable Securities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of Investments [Line Items]	'	'	'	'
Cash and cash equivalents, Marketable securities, Cost	$159,777	$143,008	'	'
Cash and cash equivalents, Marketable securities, Gross Unrealized Gains	'	'	'	'
Cash and cash equivalents, Marketable securities, Gross Unrealized Losses	'	'	'	'
Cash and cash equivalents, Marketable securities, Estimated fair Value	159,777	143,008	'	'
Cash and cash equivalents	156,306	139,698	121,202	53,557
Marketable Security, Current	3,471	3,310	'	'
Marketable Security, Long Term	'	'	'	'
Money market funds [Member]	'	'	'	'
Schedule of Investments [Line Items]	'	'	'	'
Marketable security, Amortized Cost	100,395	11,698	'	'
Marketable security, Estimated fair Value	100,395	11,698	'	'
Cash and cash equivalents	100,395	11,698	'	'
Marketable Security, Long Term	'	'	'	'
Bank CDs [Member]	'	'	'	'
Schedule of Investments [Line Items]	'	'	'	'
Marketable security, Amortized Cost	410	987	'	'
Marketable security, Gross Unrealized Gains	'	'	'	'
Marketable security, Gross Unrealized Losses	'	'	'	'
Marketable security, Estimated fair Value	410	987	'	'
Cash and cash equivalents	'	'	'	'
Marketable Security, Current	410	987	'	'
Marketable Security, Long Term	'	'	'	'
Mutual funds [Member]	'	'	'	'
Schedule of Investments [Line Items]	'	'	'	'
Marketable security, Amortized Cost	3,061	2,323	'	'
Marketable security, Gross Unrealized Gains	'	'	'	'
Marketable security, Gross Unrealized Losses	'	'	'	'
Marketable security, Estimated fair Value	3,061	2,323	'	'
Cash and cash equivalents	'	'	'	'
Marketable Security, Current	3,061	2,323	'	'
Marketable Security, Long Term	'	'	'	'
Bank Deposits [Member]	'	'	'	'
Schedule of Investments [Line Items]	'	'	'	'
Bank deposits, Cost	55,911	128,000	'	'
Bank deposits, Gross Unrealized Gains	'	'	'	'
Bank deposits, Gross Unrealized Losses	'	'	'	'
Bank deposits, Estimated fair Value	55,911	128,000	'	'
Cash and cash equivalents	$55,911	$128,000	'	'

Balance_Sheet_Account_Detail_S1

Balance Sheet Account Detail - Schedule of Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, at cost	$10,605	$9,863
(Less): accumulated depreciation and amortization	-9,070	-7,315
Property and equipment, net	1,535	2,548
Computers and software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, at cost	5,154	4,540
Lab and media equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, at cost	1,063	886
Office furniture and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, at cost	1,575	1,492
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, at cost	2,813	2,799
Assets held under capital lease obligations [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, at cost	'	$146

Balance_Sheet_Account_Detail_C

Balance Sheet Account Detail - Components of Inventories, Net (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]	'	'
Raw materials	$1,794	$887
Work in process	3,312	7,302
Finished goods	8,413	6,289
Inventories	$13,519	$14,478

Balance_Sheet_Account_Detail_C1

Balance Sheet Account Detail - Components of Intangible Assets (Detail) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

29-May-13

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

MARQIBO IPR&D [Member]

MELPHALAN IPR&D [Member]

Marqibo developed technology [Member]

ZEVALIN marketing rights [Member]

FUSILEV developed technology [Member]

FOLOTYN distribution rights [Member]

FOLOTYN developed technology [Member]

U.S. [Member]

Ex-U.S. [Member]

Product Rights [Line Items]

Historical Cost

$280,668

$228,468

$17,600

$7,700

$26,900

$41,900

$23,490

$16,778

$27,900

Historical Cost

118,400

Accumulated Amortization

-48,975

-27,879

-1,107

-23,455

-19,735

-5,343

-2,192

-4,821

-2,980

-3,662

-895

Accumulated Amortization

-10,587

-2,077

Foreign Currency Translation

682

-355

682

-355

Foreign Currency Translation

Impairment

-1,023

Net Amount

$231,352

$200,234

$17,600

$7,700

$25,793

$18,445

$22,165

$18,829

$20,943

$11,957

$13,798

$23,215

$27,005

$107,813

$116,323

Amortization Period (years)

'11 years

'10 years

'8 years

'11 years

'10 years

'13 years

Remaining Amortization Period (years)

'11 years

'5 years

'6 years

'8 years

'9 years

'12 years

Balance_Sheet_Account_Detail_C2

Balance Sheet Account Detail - Components of Intangible Assets (Parenthetical) (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	29-May-13	Dec. 31, 2013
Product Rights [Line Items]	'	'
Impairment	'	$1,023
FOLOTYN distribution rights [Member]	'	'
Product Rights [Line Items]	'	'
Impairment	$1,023	$1,023

Balance_Sheet_Account_Detail_E

Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Investment Holdings [Abstract]	'
2014	$22,468
2015	22,468
2016	22,468
2017	22,468
2018	22,313
2019 and thereafter	93,867
Intangible Assets, Net Total	$206,052

Balance_Sheet_Account_Detail_S2

Balance Sheet Account Detail - Schedule of Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'
Foreign exchange translation effects	$104	($37)
Goodwill	18,501	7,279
ZEVALIN Rights [Member]	'	'
Goodwill [Line Items]	'	'
Acquisition	2,525	2,525
Allos Therapeutics, Inc. [Member]	'	'
Goodwill [Line Items]	'	'
Acquisition	5,346	4,791
Talon [Member]	'	'
Goodwill [Line Items]	'	'
Acquisition	$10,526	'

Balance_Sheet_Account_Detail_S3

Balance Sheet Account Detail - Summary of Other Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Investments in equity securities	$3,593	$2,476
Deposits	190	304
Debt issuance cost	3,432	814
Life insurance cash surrender value	5,361	2,881
Other assets	$12,576	$6,475

Balance_Sheet_Account_Detail_S4

Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Obligations (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Payables And Accruals [Abstract]	'	'
Trade payables	$12,796	$30,814
Accrued rebates	28,893	11,023
Accrued product royalty	9,498	12,275
Allowance for returns	2,900	5,056
Accrued data and distribution fees	2,430	8,449
Accrued GPO administrative fees	2,327	2,650
Inventory management fee	616	3,050
Accrued income taxes	3	2,522
Allowance for chargebacks	5,074	15,153
Accrued drug development costs	6,433	11,441
Other accrued obligations	8,867	2,819
Accounts payable and other accrued obligations	$79,837	$105,252

Balance_Sheet_Account_Detail_S5

Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Rebates and Chargebacks [Member]	'	'
Schedule of Investments [Line Items]	'	'
Balance as of December 31, 2011	$26,176	$9,064
Allos accruals assumed	'	2,371
Add: provisions (recovery)	63,609	91,059
Less: credits or actual allowances	-55,818	-76,318
Balance as of December 31, 2012	33,967	26,176
Data and Distribution GPO Fees and Inventory Management Fees [Member]	'	'
Schedule of Investments [Line Items]	'	'
Balance as of December 31, 2011	14,149	9,808
Allos accruals assumed	'	182
Add: provisions (recovery)	19,067	32,793
Less: credits or actual allowances	-27,843	-28,634
Balance as of December 31, 2012	5,373	14,149
Prompt Pay Discount [Member]	'	'
Schedule of Investments [Line Items]	'	'
Balance as of December 31, 2011	1,451	992
Add: provisions (recovery)	183	4,814
Less: credits or actual allowances	-1,317	-4,355
Balance as of December 31, 2012	317	1,451
Returns [Member]	'	'
Schedule of Investments [Line Items]	'	'
Balance as of December 31, 2011	5,056	4,000
Allos accruals assumed	'	941
Add: provisions (recovery)	-2,034	159
Less: credits or actual allowances	-122	-44
Balance as of December 31, 2012	$2,900	$5,056

Balance_Sheet_Account_Detail_S6

Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Other Liabilities Disclosure [Abstract]	'	'
Accrued executive deferred compensation	$3,949	$2,366
Deferred rent (non-current portion)	366	571
Business acquisition liability	298	298
Other tax liabilities	1,352	1,132
Other long-term liabilities	$5,965	$4,367

GrosstoNet_Product_Sales_Recon

Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales Revenue Net [Abstract]	'	'	'
Gross product sales	$224,301	$383,817	$220,670
Rebates and government chargebacks	-63,610	-91,059	-22,190
Distribution and data fees and group purchasing organizations fees	-19,067	-32,793	-11,637
Prompt pay discounts	-183	-4,814	-4,086
Product returns allowance	2,034	-159	-2,094
Product sales, net	$143,475	$254,992	$180,663

Product_Sales_Net_by_Geographi2

Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Geography (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales Information [Line Items]	'	'	'
Product sales, net	$143,475	$254,992	$180,663
Percentage of product sales, net	100.00%	100.00%	100.00%
United States [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	133,462	245,697	180,663
Percentage of product sales, net	93.00%	96.40%	'
Total International [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	10,013	9,295	'
Percentage of product sales, net	7.00%	3.60%	'
Total International [Member] \| Europe [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	3,953	3,113	'
Percentage of product sales, net	2.80%	1.20%	'
Total International [Member] \| Asia Pacific [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	$6,060	$6,182	'
Percentage of product sales, net	4.20%	2.40%	'

Product_Sales_Net_by_Geographi3

Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Product Line (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales Information [Line Items]	'	'	'
Product sales, net	$143,475	$254,992	$180,663
Percentage of product sales, net	100.00%	100.00%	100.00%
FUSILEV [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	68,397	204,253	153,110
FOLOTYN [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	44,370	20,412	'
ZEVALIN [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	29,393	30,327	27,553
MARQIBO [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Product sales, net	$1,315	'	'
Sales [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Percentage of product sales, net	100.00%	100.00%	15.30%
Sales [Member] \| FUSILEV [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Percentage of product sales, net	47.70%	80.10%	84.70%
Sales [Member] \| FOLOTYN [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Percentage of product sales, net	30.90%	8.00%	'
Sales [Member] \| ZEVALIN [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Percentage of product sales, net	20.50%	11.90%	'
Sales [Member] \| MARQIBO [Member]	'	'	'
Sales Information [Line Items]	'	'	'
Percentage of product sales, net	0.90%	'	'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2009

Dec. 31, 2013

Plans

Upon Termination of Employment [Member]

In the Event of Optionee's Death, Disability or Retirement [Member]

Restricted stock awards [Member]

Unvested stock options [Member]

Maximum [Member]

Minimum [Member]

2009 Incentive Award Plan [Member]

2013 Stock Incentive Plan [Member]

Purchase Plan [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock authorized for issuance under incentive plan

10,000,000

5,000,000

Increased number of common stock shares

2,500,000

Issuance of common stock

30.00%

Incentive awards available for grant

5,700,000

50,000

10,000,000

Number of stock incentive plans

Exercise price fair value

100.00%

Stock based award vest

8.00%

5.00%

25.00%

Restricted stock vesting period

Restricted stock exercised period

'90 days

'365 days

Percentage of common stock purchase price

15.00%

Purchase Plan offering period

'6 months

Maximum number of common stock shares available for purchase per participant

50,000

Maximum number of common stock value available for purchase per participant

$25,000

Increase in number of shares of common stock available for issuance under the purchase plan

1,000,000

Unrecognized compensation expense

$6,500,000

$12,400,000

Weighted average period to recognize compensation expense

'2 years 4 months 24 days

'2 years 6 months 15 days

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total share-based compensation expense	$12,779	$14,884	$22,237
Selling, general and administrative [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total share-based compensation expense	10,762	13,041	20,609
Research and development [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Total share-based compensation expense	$2,017	$1,843	$1,628

StockBased_Compensation_Fair_V

Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Expected option life (in years)	'4 years 11 months 12 days	'4 years 6 months	'4 years 11 months 5 days
Risk-free interest rate, Minimum	0.35%	0.34%	0.82%
Risk-free interest rate, Maximum	0.78%	0.51%	2.40%
Volatility, Minimum	58.30%	64.20%	'
Volatility, Maximum	71.50%	73.60%	'
Volatility	'	'	55.80%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average grant-date fair value per stock option	$4.66	$6.20	$2.65

StockBased_Compensation_Fair_V1

Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected option life	'4 years 11 months 12 days	'4 years 6 months	'4 years 11 months 5 days
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected option life	'10 years	'10 years	'10 years

StockBased_Compensation_Summar1

Stock-Based Compensation - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Number of Shares, Outstanding, Beginning Balance	10,399,265	10,185,521	8,397,094
Weighted-Average Exercise Price/Share, Outstanding, Beginning Balance	$6.57	$5.46	$4.17
Number of Shares, Granted	2,041,300	1,821,915	3,622,150
Number of Shares, Exercised	-825,884	-1,287,430	-1,126,257
Number of Shares, Forfeited	-202,882	-316,825	-547,479
Number of Shares, Expired	-82,581	-3,916	-159,987
Number of Shares, Outstanding, Ending Balance	11,329,218	10,399,265	10,185,521
Number of Shares, Vested (exercisable) - December 31, 2013	7,876,025	'	'
Weighted-Average Exercise Price/Share, Granted	$8.92	$11.57	$7.92
Number of Shares, Unvested (unexercisable) - December 31, 2013	3,453,193	'	'
Weighted-Average Exercise Price/Share, Exercised	$4.40	$4.52	$4.07
Weighted-Average Exercise Price/Share, Forfeited	$8.22	$7.93	$4.81
Weighted-Average Exercise Price/Share, Expired	$8.91	$7.69	$5.17
Weighted-Average Exercise Price/Share Outstanding, Ending Balance	$7.10	$6.57	$5.46
Weighted-Average Exercise Price/Share, Vested (exercisable) - December 31, 2013	$6.11	'	'
Weighted-Average Exercise Price/Share, Unvested (unexercisable) - December 31, 2013	$9.38	'	'
Weighted-Average Remaining Contractual Term (Years), Outstanding	'7 years	'	'
Weighted-Average Remaining Contractual Term (Years), Vested (exercisable) - December 31, 2013	'6 years 2 months 12 days	'	'
Weighted-Average Remaining Contractual Term (Years), Unvested (unexercisable) - December 31, 2013	'8 years 10 months 24 days	'	'
Stock options exercised, Intrinsic value	$3,435	$11,500	$8,255
Aggregate Intrinsic Value	25,849	'	'
Aggregate Intrinsic Value, Vested (exercisable) - December 31, 2013	24,080	'	'
Aggregate Intrinsic Value, Unvested (unexercisable) - December 31, 2013	$1,770	'	'

StockBased_Compensation_Summar2

Stock-Based Compensation - Summary of Stock Option Grants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Granted Stock Options Outstanding	11,329,218
Weighted-Average Remaining Contractual Life (Years)	'7 years
Weighted-Average Exercise Price	$7.10
Granted Stock Options Exercisable	7,876,025
Weighted-Average Exercise Price	$6.11
Exercise Price Range One [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, Range lower limit	$0.92
Exercise Price, Range upper limit	$3.15
Granted Stock Options Outstanding	1,192,794
Weighted-Average Remaining Contractual Life (Years)	'4 years 6 months
Weighted-Average Exercise Price	$2.16
Granted Stock Options Exercisable	1,192,794
Weighted-Average Exercise Price	$2.16
Exercise Price Range Two [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, Range lower limit	$3.55
Exercise Price, Range upper limit	$4.95
Granted Stock Options Outstanding	1,924,904
Weighted-Average Remaining Contractual Life (Years)	'5 years 10 months 24 days
Weighted-Average Exercise Price	$4.23
Granted Stock Options Exercisable	1,865,794
Weighted-Average Exercise Price	$4.23
Exercise Price Range Three [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, Range lower limit	$5.05
Exercise Price, Range upper limit	$6.90
Granted Stock Options Outstanding	2,862,699
Weighted-Average Remaining Contractual Life (Years)	'5 years 6 months
Weighted-Average Exercise Price	$6.26
Granted Stock Options Exercisable	2,565,220
Weighted-Average Exercise Price	$6.19
Exercise Price Range Four [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, Range lower limit	$7
Exercise Price, Range upper limit	$8.99
Granted Stock Options Outstanding	2,329,167
Weighted-Average Remaining Contractual Life (Years)	'8 years 2 months 12 days
Weighted-Average Exercise Price	$8.17
Granted Stock Options Exercisable	1,147,138
Weighted-Average Exercise Price	$8.26
Exercise Price Range Five [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, Range lower limit	$9
Exercise Price, Range upper limit	$16.32
Granted Stock Options Outstanding	3,019,654
Weighted-Average Remaining Contractual Life (Years)	'9 years 2 months 12 days
Weighted-Average Exercise Price	$10.86
Granted Stock Options Exercisable	1,105,079
Weighted-Average Exercise Price	$11.09

StockBased_Compensation_Summar3

Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Number of Restricted Stock Awards, Unvested, Beginning Balance	1,034,604	952,525	359,500
Number of Restricted Stock Awards, Granted	523,800	586,639	1,781,000
Number of Restricted Stock Awards, Vested	-501,660	-472,160	-1,104,025
Number of Restricted Stock Awards, Forfeited	-49,625	-32,400	-83,950
Number of Restricted Stock Awards, Unvested, Ending Balance	1,007,119	1,034,604	952,525
Weighted Average Fair Value per Share at Grant Date, Beginning Balance	$11	$10.11	$3.96
Weighted Average Fair Value per Share at Grant Date, Granted	$8.74	$11.76	$12.48
Weighted Average Fair Value per Share at Grant Date, Vested	$9.72	$10.26	$12.33
Weighted Average Fair Value per Share at Grant Date, Forfeited	$10.60	$9.57	$4.78
Weighted Average Fair Value per Share at Grant Date, Ending Balance	$10.09	$11	$10.11

StockBased_Compensation_Fair_V2

Stock-Based Compensation - Fair Value of Restricted Stock Awards (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Restricted stock expense	$4,202	$6,500	$4,100

StockBased_Compensation_Issued

Stock-Based Compensation - Issued Shares of Common Stock (Detail) (401(k) Plan [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
401(k) Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares of common stock issued	99,359	56,254	65,889
Match contribution value	$860	$691	$593

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended				1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jun. 13, 2011	Jun. 13, 2011	Sep. 30, 2003	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
	Dec. 31, 2013	Dec. 31, 2012	Maximum [Member]	Minimum [Member]	Series E Convertible Voting Preferred Stock [Member]	Series E Convertible Voting Preferred Stock [Member]	Series E Convertible Voting Preferred Stock [Member]	Series B Junior Participating Preferred Stock [Member]	Series B Junior Participating Preferred Stock [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'	'	'	'	'	'	'	'	'
Preferred stock, shares authorized	5,000,000	5,000,000	'	'	'	2,000	2,000	1,500,000	1,500,000
Number of common shares authorized	175,000,000	175,000,000	175,000,000	100,000,000	'	'	'	'	'
New replacement rights agreement extended date	'December 13, 2020	'	'	'	'	'	'	'	'
Percentage of outstanding shares acquired to exercise preferred share rights	15.00%	'	'	'	'	'	'	'	'
Transfer of assets or earnings power	50.00%	'	'	'	'	'	'	'	'
Preferred stock issued	'	'	'	'	2,000	20	20	0	0
Preferred stock converted into common stock	'	'	'	'	4,000,000	40,000	40,000	'	'
Convertible preferred stock outstanding	'	'	'	'	'	20	20	0	0
Number of trading days consider for option to redeem preferred stock	'	'	'	'	'	'20 days	'	'	'
Dividends payable	'	'	'	'	'	$0	$0	'	'
Common stock trading price per share	$12	'	'	'	'	'	'	'	'
Cash proceeds from exchange of preferred stock	'	'	'	'	$20,000,000	'	'	'	'
Percentage of preferred stock liquidation preference common stock	120.00%	'	'	'	'	'	'	'	'
Shares of common stock issuable upon conversion or exercise of rights granted	28,100,000	'	'	'	'	'	'	'	'
Outstanding warrants expire on varying dates	'December 2015	'	'	'	'	'	'	'	'

Stockholders_Equity_Shares_of_

Stockholders' Equity - Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted (Detail)	Dec. 31, 2013
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'
Total shares of common stock reserved for future issuances	28,101,704
Series E Convertible Voting Preferred Stock [Member]	'
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'
Total shares of common stock reserved for future issuances	40,000
2018 Convertible Notes [Member]	'
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'
Total shares of common stock reserved for future issuances	11,400,000
Unvested stock options [Member]	'
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'
Total shares of common stock reserved for future issuances	11,329,218
Exercise of issued warrants [Member]	'
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'
Total shares of common stock reserved for future issuances	445,000
ESPP shares reserved [Member]	'
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'
Total shares of common stock reserved for future issuances	4,540,986
Long-term retention and management incentive plan shares [Member]	'
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'
Total shares of common stock reserved for future issuances	346,500

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'	'	'
Weighted Average Exercise Price, Granted	$7.51	'	'
Weighted Average Exercise Price, Exercised	'	$1.79	'
Weighted Average Exercise Price, Beginning Balance	$5.45	$5.04	$6.45
Weighted Average Exercise Price, Expired	'	'	$6.62
Weighted Average Exercise Price, Ending Balance	$6.39	$5.45	$5.04
Weighted Average Exercise Price, Exercisable	$6.29	'	'
Exercise of issued warrants [Member]	'	'	'
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]	'	'	'
Number of Shares, Outstanding Beginning	395,000	445,000	4,192,312
Number of Shares, Granted	50,000	'	'
Number of Shares, Exercised	'	-50,000	'
Number of Shares, Expired	'	'	-3,747,312
Number of Shares, Outstanding Ending	445,000	395,000	445,000
Exercisable, Number of Shares Outstanding	407,500	'	'

Net_Loss_Income_Per_Share_Comp

Net (Loss) Income Per Share - Computation of Net (Loss) Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net (loss) income	'	'	'	'	'	'	'	'	($62,134)	$94,201	$49,931
Weighted average shares - basic	'	'	'	'	'	'	'	'	60,729,128	58,588,916	53,272,767
Net (loss) income per share - basic	($0.63)	($0.13)	($0.16)	($0.09)	$0.13	$0.37	$0.31	$0.80	($1.02)	$1.61	$0.94
Weighted average shares - diluted	'	'	'	'	'	'	'	'	60,729,128	64,637,256	57,959,714
Net (loss) income per share - diluted	($0.63)	($0.13)	($0.16)	($0.09)	$0.12	$0.33	$0.29	$0.72	($1.02)	$1.46	$0.86

Net_Loss_Income_Per_Share_Sche

Net (Loss) Income Per Share - Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net income (loss)	($39,166)	($7,812)	($9,721)	($5,435)	$7,489	$21,524	$18,350	$46,838	($62,134)	$94,201	$49,931
Weighted-Average Shares Outstanding (Denominator), Basic	'	'	'	'	'	'	'	'	60,729,128	58,588,916	53,272,767
Dilutive preferred shares	'	'	'	'	'	'	'	'	'	40,000	40,000
Dilutive common stock options	'	'	'	'	'	'	'	'	'	4,749,299	4,185,224
Change in common stock related to Targent and management incentive plan milestones as if they had been issued at the beginning of the quarter earned	'	'	'	'	'	'	'	'	'	'	248,193
Incremental common stock assumed issued on exercise of in the money warrants	'	'	'	'	'	'	'	'	'	224,437	200,656
Unvested restrictive stock awards	'	'	'	'	'	'	'	'	'	1,034,604	12,874
Weighted-Average Shares Outstanding (Denominator), Diluted	'	'	'	'	'	'	'	'	60,729,128	64,637,256	57,959,714
Net Income Per Share, Basic	($0.63)	($0.13)	($0.16)	($0.09)	$0.13	$0.37	$0.31	$0.80	($1.02)	$1.61	$0.94
Net Income Per Share, Diluted	($0.63)	($0.13)	($0.16)	($0.09)	$0.12	$0.33	$0.29	$0.72	($1.02)	$1.46	$0.86

Net_Income_Loss_Per_Share_Sche

Net Income (Loss) Per Share - Schedule of Securities Excluded from Calculation of Net (Loss) per Share (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive excluded from computation of earnings per share amount	4,486,160	'	'
Preferred Stock [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive excluded from computation of earnings per share amount	40,000	'	'
Common Stock Warrants [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive excluded from computation of earnings per share amount	160,816	'	'
2018 Convertible Notes [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive excluded from computation of earnings per share amount	343,600	'	'
Common stock options [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive excluded from computation of earnings per share amount	2,934,625	'	'
Restricted stock awards [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive excluded from computation of earnings per share amount	1,007,119	'	'

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Assets:	'	'
Deferred compensation investments, including life insurance cash surrender value	$5,361	$2,881
Total Assets	112,820	20,369
Liabilities:	'	'
Deferred executive compensation liability	3,949	2,365
Deferred development costs	17,742	12,233
Deferred payment contingency	'	2,287
Ligand Contingent Consideration	4,000	'
Talon CVR	4,329	'
Total Liabilities	30,020	16,885
Bank CDs [Member]	'	'
Assets:	'	'
Marketable securities, fair value	410	987
Money market funds [Member]	'	'
Assets:	'	'
Marketable securities, fair value	100,395	11,698
Mutual funds [Member]	'	'
Assets:	'	'
Marketable securities, fair value	3,061	2,323
Equity Securities [Member]	'	'
Assets:	'	'
Marketable securities, fair value	3,593	2,480
Level 1 [Member]	'	'
Assets:	'	'
Total Assets	3,593	2,480
Level 1 [Member] \| Equity Securities [Member]	'	'
Assets:	'	'
Marketable securities, fair value	3,593	2,480
Level 2 [Member]	'	'
Assets:	'	'
Deferred compensation investments, including life insurance cash surrender value	5,361	2,881
Total Assets	109,227	17,889
Liabilities:	'	'
Deferred executive compensation liability	3,949	2,365
Total Liabilities	3,949	2,365
Level 2 [Member] \| Bank CDs [Member]	'	'
Assets:	'	'
Marketable securities, fair value	410	987
Level 2 [Member] \| Money market funds [Member]	'	'
Assets:	'	'
Marketable securities, fair value	100,395	11,698
Level 2 [Member] \| Mutual funds [Member]	'	'
Assets:	'	'
Marketable securities, fair value	3,061	2,323
Level 3 [Member]	'	'
Liabilities:	'	'
Deferred development costs	17,742	12,233
Deferred payment contingency	'	2,287
Ligand Contingent Consideration	4,000	'
Talon CVR	4,329	'
Total Liabilities	$26,071	$14,520

Fair_Value_Measurements_Activi

Fair Value Measurements - Activity of Level 3 Inputs Measured on Recurring Basis (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Ending Balance	$26,071	$14,520
Deferred development costs [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Transfers in / (out) of Level 3	5,509	12,233
Deferred payment contingency [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Transfers in / (out) of Level 3	-2,287	2,287
Ligand Contingent Consideration [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Transfers in / (out) of Level 3	4,000	'
Talon CVR [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Transfers in / (out) of Level 3	$4,329	'

Business_Combinations_Addition

Business Combinations - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended	12 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Jul. 17, 2013	Dec. 31, 2013	Dec. 31, 2013
Business Acquisition [Line Items]	'	'	'
Milestone payments methods	'If all sales and regulatory approval milestones are achieved, as summarized below: b" $5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year b" $10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year b" $25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year b" $50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year b" $100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year b" $5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion	'	'
Milestone net sales achievement	'	'	$6,000,000
Direct costs of acquisition	'	5,700,000	5,700,000
Goodwill	'	10,526,000	10,526,000
Net assets acquired	'	33,574,000	33,574,000
Total purchase consideration	'	44,100,000	44,100,000
License fees received	'	'	3,000,000
Aggregate transaction costs expensed	'	'	15,000
Milestone Payments [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Milestone net sales achievement	5,000,000	'	66,000,000
Milestone net sales achievement	30,000,000	'	'
Milestone Payment One [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Milestone net sales achievement	10,000,000	'	'
Milestone net sales achievement	60,000,000	'	'
Milestone Payment Two [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Milestone net sales achievement	25,000,000	'	'
Milestone net sales achievement	100,000,000	'	'
Milestone Payment Three [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Milestone net sales achievement	50,000,000	'	'
Milestone net sales achievement	200,000,000	'	'
Milestone Payment Four [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Milestone net sales achievement	100,000,000	'	'
Milestone net sales achievement	400,000,000	'	'
Menadione Topical Lotion [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Milestone net sales achievement	5,000,000	'	'
Minimum [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Royalties payout percentage on net sales of licensed products	'	15.00%	15.00%
Maximum [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Royalties payout percentage on net sales of licensed products	'	25.00%	25.00%
Talon Therapeutics, Inc. [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Securities purchase agreement date	'	'	16-Jul-13
Additional shares business acquisition date	'	'	17-Jul-13
Revenue derived from the former business	'	1,300,000	'
Cash consideration	'	'	11,300,000
Shares issued in acquisition	3	'	'
Common stock value, per share	'	'	$8.77
Common stock value assigned	26,300,000	26,300,000	26,300,000
Estimated fair value of acquisition	6,500,000	6,500,000	6,500,000
Contingent value rights future cash payments	195,000,000	'	'
Contingent value rights valuation description	'The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs - see Note 3 (x)).	'	'
Contingent value rights discount rate	25.00%	'	'
Goodwill	'	10,526,000	10,526,000
Net assets acquired	'	33,574,000	33,574,000
Total purchase consideration	'	44,100,000	44,100,000
Talon Therapeutics, Inc. [Member] \| Minimum [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Contingent value rights expected rate	50.00%	'	'
Talon Therapeutics, Inc. [Member] \| Maximum [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Contingent value rights expected rate	100.00%	'	'
Allos Therapeutics, Inc. [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Total purchase consideration	'	$205,200,000	$205,200,000
In-process research and development [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Estimated cash flow period	'	'	'10 years
Estimated cash flow discount rate	'	25.00%	25.00%

Business_Combinations_Acquisit

Business Combinations - Acquisition-Date Fair Value of Consideration Transferred (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Jul. 17, 2013
Business Acquisition [Line Items]	'	'
Total purchase consideration	$44,100	'
Captisol-enabled, propylene glycol-free melphalan rights [Member]	'	'
Business Acquisition [Line Items]	'	'
Cash consideration	3,000	'
Ligand Contingent Consideration	4,700	'
Total purchase consideration	7,700	'
Talon Therapeutics, Inc. [Member]	'	'
Business Acquisition [Line Items]	'	'
Cash consideration	11,300	'
CVR	6,500	6,500
Spectrum shares of common stock	26,300	26,300
Total purchase consideration	$44,100	'

Business_Combinations_Summary_

Business Combinations - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Loans At Acquisition Date [Line Items]	'
Net assets acquired	$33,574
Goodwill	10,526
Talon Therapeutics, Inc. [Member]	'
Loans At Acquisition Date [Line Items]	'
Cash and equivalents	131
Inventory	611
Prepaid expenses and other current assets	109
Property and equipment	30
Identifiable intangible assets	44,500
Total assets acquired	45,381
Accounts payable & accrued liabilities	5,231
Deferred tax liability	6,576
Total liabilities assumed	11,807
Net assets acquired	33,574
Goodwill	$10,526

Business_Combinations_Amortiza

Business Combinations - Amortization Period for such Intangible Assets Acquired (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Talon Therapeutics, Inc. [Member]	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Total identifiable intangible assets	44,500
Developed technology - MARQIBO for ALL [Member]	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Amortization Period	'13 years
Developed technology - MARQIBO for ALL [Member] \| Talon Therapeutics, Inc. [Member]	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Total identifiable intangible assets	26,900
IPR&D - MARQIBO for NHL [Member] \| Talon Therapeutics, Inc. [Member]	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Total identifiable intangible assets	17,600

Business_Combinations_Suppleme

Business Combinations - Supplemental Pro Forma Financial Information (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Combinations [Abstract]	'	'
Pro Forma Total revenues	$155,854	$267,707
Pro Forma Total costs and operating expenses	200,651	210,433
Pro Forma Net (loss) income	($68,146)	$57,274
Pro Forma Net (loss) income per share - basic	($1.12)	$0.98
Pro Forma Net (loss) income per share - diluted	($1.12)	$0.89

Business_Combinations_Change_i

Business Combinations - Change in Fair Value of Contingent Consideration Related to Acquisition (Detail) (USD $)	10 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013
	Ligand Pharmaceuticals Inc [Member]	Talon Therapeutics, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]	'	'
Fair value, Beginning Balance	$4,700	$6,500
Fair value adjustment for year ended December 31, 2013	-700	-2,171
Fair value, Ending Balance	$4,000	$4,329

Revolving_Line_of_Credit_Addit

Revolving Line of Credit - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Disclosure [Abstract]	'	'	'
Credit agreement revolving line of credit facility	$50	'	'
Credit facility expiry date	5-Sep-14	'	'
Credit facility, minimum interest rate	2.75%	'	'
Credit facility, maximum interest rate	4.25%	'	'
Loan costs and fees to be amortized	1	'	'
Percentage of maximum amount of unused line fee	0.63%	'	'
Percentage of minimum amount of unused line fee	0.38%	'	'
Interest expense	$1.20	$0.50	$0

Convertible_Senior_Notes_Addit

Convertible Senior Notes - Additional Information (Detail) (USD $)	12 Months Ended			12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
				2.75% Convertible Senior Notes Due 2018 [Member]	2.75% Convertible Senior Notes Due 2018 [Member]	2.75% Convertible Senior Notes Due 2018 [Member]
					Minimum [Member]	Maximum [Member]
Debt Disclosure [Line Items]	'	'	'	'	'	'
Sale of convertible notes, principal amount	'	'	'	$120,000,000	'	'
Conversion rate, shares	'	'	'	95	'	'
Conversion rate, price per share	'	'	'	$1,000	'	'
Common shares converted value	37,000	'	'	11,400,000	'	'
Money conversion price per share	'	'	'	$10.53	'	'
Interest rate	'	'	'	2.75%	'	'
Convertible senior notes maturity date	'	'	'	15-Dec-18	'	'
Net proceeds from convertible notes	'	'	'	115,400,000	'	'
Professional fee	'	'	'	4,600,000	'	'
Additional paid in capital	'	518,144,000	463,710,000	13,100,000	'	'
Strike price per share	'	'	'	$14.03	'	'
Common shares sold	'	64,000	60,000	11,400,000	'	'
Debt convertible trading days	'	'	'	'	'20 days	'
Debt convertible consecutive trading days	'	'	'	'	'5 days	'30 days
Threshold percentage of conversion price	'	'	'	130.00%	'	'
Convertible senior notes trading price	'	'	'	$1,000	'	'
Percentage of product of last reported sale price of common stock	'	'	'	98.00%	'	'
Convertible senior notes conversion description	'	'	'	'Prior to June 15, 2018, holders may convert all or a portion of their 2018 Notes only under the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after March 31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Notes for such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; or (4) at any time we have not received stockholder approval, as that term is defined in the Indenture. On and after June 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Notes at any time, regardless of the foregoing circumstances.	'	'

Convertible_Senior_Notes_Carry

Convertible Senior Notes - Carrying Values of 2018 Convertible Notes (Detail) (2018 Convertible Notes [Member], USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
2018 Convertible Notes [Member]	'
Debt Instrument [Line Items]	'
Principal amount	$120,000
(Less): Unamortized debt discount (amortized through December 2018)	-28,520
December 31, 2013 net carrying amount of 2018 Convertible Notes	$91,480

Convertible_Senior_Notes_Compo

Convertible Senior Notes - Components of Total Interest Expense Recognized (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Equity Method Investments And Cost Method Investments [Abstract]	'
Contractual coupon interest expense	$73
Amortization of debt issuance costs	101
Accretion of debt discount	43
Total	$217
Effective interest rate	8.59%

Mundipharma_Agreement_Addition

Mundipharma Agreement - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Company determined development payment	$194,639,000	$186,933,000	$136,417,000	'
Deferred development cost	'	'	'	12,300,000
Mundipharma [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Company determined development payment	7,000,000	'	'	'
Development cost liability	17,700,000	'	'	'
Maximum [Member] \| Regulatory [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Potential milestone payments	16,000,000	'	'	'
Maximum [Member] \| Commercial progress and sales-dependent [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Potential milestone payments	$107,000,000	'	'	'

Mundipharma_Agreement_Schedule

Mundipharma Agreement - Schedule of Drug Development Liability Adjustments (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Schedule Of Accrued Liabilities [Line Items]	'
Beginning Balance	$856
Amended agreement payment receipt	-7,000
Ending Balance	3,119
FOLOTYN [Member]	'
Schedule Of Accrued Liabilities [Line Items]	'
Beginning Balance	12,233
Amended agreement payment receipt	7,000
(Less): Expenses incurred	-1,491
Ending Balance	17,742
FOLOTYN [Member] \| Drug Development Liability Current [Member]	'
Schedule Of Accrued Liabilities [Line Items]	'
Beginning Balance	856
Transfer from long term to current	3,620
(Less): Expenses incurred	-1,357
Ending Balance	3,119
FOLOTYN [Member] \| Drug Development Liability Long Term [Member]	'
Schedule Of Accrued Liabilities [Line Items]	'
Beginning Balance	11,377
Transfer from long term to current	-3,620
Amended agreement payment receipt	7,000
(Less): Expenses incurred	-134
Ending Balance	$14,623

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

In Millions, unless otherwise specified

31-May-06

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Apr. 30, 2012

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

31-May-11

Apr. 30, 2011

Dec. 31, 2011

Dec. 31, 2013

Feb. 28, 2010

Feb. 14, 2014

Dec. 31, 2013

Oct. 31, 2008

USD ($)

ZEVALIN [Member]

FOLOTYN [Member]

FUSILEV [Member]

Minimum [Member]

Maximum [Member]

Targent, Inc [Member]

Nippon Kayaku [Member]

TopoTarget [Member]

Henderson [Member]

Irvine [Member]

Allergan [Member]

USD ($)

Licensing Agreements [Member]

USD ($)

FOLOTYN [Member]

USD ($)

Subsequent Event [Member]

USD ($)

EUR (€)

Country

USD ($)

Long-term Purchase Commitment [Line Items]

Non-cancelable operating lease expiring

30-Apr-14

31-May-19

Rental expense

$1.20

$0.90

$0.70

Milestone payments

Additional amount paid by RIT to Biogen

5.5

Additional milestone payment upon the achievement of an additional FDA approval milestone

Minimum number of countries outside U.S. approved ZEVALIN for treatment

Fees paid to Bayer for acquiring licensing rights

Payment to Merck & Cie for the achievement of FDA approval of FUSILEV

0.1

Amount receivable on approval of oral form of FUSILEV

0.2

Shares of common stock, issued

0.7

Capitalization associated with milestone as intangible assets

6.3

Common stock issued, shares

0.6

Cash paid for sales milestone achieved

Aggregate amount received from first sales milestone

Percentage of royalty on annual worldwide sales under condition one

8.00%

15.00%

25.00%

Percentage of royalty on annual worldwide sales under condition two

9.00%

Percentage of royalty on annual worldwide sales under condition three

11.00%

Amount of annual worldwide sales on which royalty is payable under condition one

150

Amount of annual worldwide sales on which royalty is payable under condition two

150

300

Amount of annual worldwide sales on which royalty is payable under condition three

300

License fees received

Additional license fees

Percentage of royalties on net sale of licensed products

15.00%

25.00%

Up-front non-refundable payment

41.5

Upfront fee

Payment related to agreement

Payment on achievement of commercialization milestones

126

Percentage of development cost

70.00%

Percentage of development cost that is funded by TopoTarget for joint development plan

30.00%

Percentage of required payment to be paid for the cost incurred

50.00%

Upfront fee

Additional payments based on the achievement of certain development

313

Shares of common stock, issued

Notice period for termination of agreement

'180 days

Deferrals and contributions

$3.90

$2.40

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
2014	$849
2015	950
2016	892
2017	843
2018	868
Operating lease future minimum payments, Total	$4,402

Income_Taxes_Components_of_Los

Income Taxes - Components of (Loss) Income before (Provision) Benefit for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
United States	($30,437)	$82,165	$53,834
Foreign	-6,199	-2,235	-199
(Loss) income before income taxes	($36,636)	$79,930	$53,635

Income_Taxes_Provision_Benefit

Income Taxes - Provision (Benefit) for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	($8,357)	$16,222	$1,255
State	-691	3,412	2,449
Foreign	'	'	'
Current, total	-9,048	19,634	3,704
Deferred:	'	'	'
Federal	36,183	-24,013	'
State	-1,637	-9,892	'
Foreign	'	'	'
Deferred, total	34,546	-33,905	'
Provision (Benefit) for income taxes	$25,498	($14,271)	$3,704

Income_Taxes_Income_Tax_Provis

Income Taxes - Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Tax provision (benefit) computed at the federal statutory rate	($12,822)	$27,975	$18,250
State tax, net of federal benefit	-246	2,442	2,918
Expired tax attributes	'	'	385
Research credits	-2,254	-2,129	-1,464
Benefits from credit study	'	-4,148	'
Common stock warrant liability	'	'	1,186
Transaction costs	880	1,497	'
Officers compensation	2,178	2,908	3,801
Stock based compensation	501	134	1,676
Permanent items and other	-1,080	2,111	2,039
Domestic manufacturing deduction	767	-1,262	'
Tax differential on foreign earnings	1,123	382	'
Change in tax rate	-283	338	'
Valuation allowance	36,734	-44,519	-25,087
Provision (Benefit) for income taxes	$25,498	($14,271)	$3,704

Income_Taxes_Components_of_Com

Income Taxes - Components of Company's Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carry forwards	$46,482	$45,391
Research credits	8,066	1,848
Stock based compensation	3,486	2,896
Deferred revenue	58	4,596
Development costs	6,495	5,298
Returns and allowances	3,117	7,889
Other, net	5,551	6,021
Total deferred tax assets before valuation allowance	73,255	73,246
Valuation allowance	-49,586	-1,818
Total deferred tax assets	23,669	72,121
Deferred tax liabilities:	'	'
Basis difference in debt	-1,082	'
Depreciation and amortization differences	-28,096	-36,372
Net deferred tax (liability) asset	($5,509)	$35,749

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Line Items]	'	'	'
Research and development tax credits	$8,066,000	$1,848,000	'
Unrecognized tax benefits, if recognized, would affect the effective tax rate	0.3	5,200,000	0.2
Reduction tax credits carryovers	800,000	'	'
Reduction operating loss carryovers	1,600,000	'	'
Examination tax	0	'	'
Federal [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Net operating loss carryforwards	117,400,000	'	'
Net operating loss carryforwards expiration year	'2018	'	'
Research and development tax credits	6,900,000	'	'
Research and development tax credits beginning expiration year	'2026	'	'
State [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Net operating loss carryforwards	132,000,000	'	'
Net operating loss carryforwards expiration year	'2014	'	'
Research and development tax credits	2,200,000	'	'
Foreign [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Net operating loss carryforwards	$4,100,000	'	'
Net operating loss carryforwards expiration year	'2028	'	'

Income_Taxes_Summary_of_Unreco

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Balance at beginning of year	$5,482	$3,928	$2,803
Adjustments related to prior year tax positions	-200	-527	5
Increases related to current year tax positions	648	2,515	1,120
Decreases due to settlements	-1,227	-434	'
Decreases related to prior year tax positions	-2,491	'	'
Balance at end of year	$2,212	$5,482	$3,928

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event [Member], TopoTarget [Member], USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 14, 2014
Subsequent Event [Member] \| TopoTarget [Member]	'
Subsequent Event [Line Items]	'
Cash paid for sales milestone achieved	$10
Common stock issued, shares	1,000,000

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data - Summary of Selected Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$41,516	$42,439	$33,232	$38,667	$70,104	$69,042	$68,702	$59,859	$155,854	$267,707	$192,963
Operating income (loss)	-6,512	-13,287	-12,529	-6,457	11,041	23,109	23,028	23,596	-38,785	80,774	56,546
Net income	($39,166)	($7,812)	($9,721)	($5,435)	$7,489	$21,524	$18,350	$46,838	($62,134)	$94,201	$49,931
Net Income Per Share, Basic	($0.63)	($0.13)	($0.16)	($0.09)	$0.13	$0.37	$0.31	$0.80	($1.02)	$1.61	$0.94
Net Income Per Share, Diluted	($0.63)	($0.13)	($0.16)	($0.09)	$0.12	$0.33	$0.29	$0.72	($1.02)	$1.46	$0.86

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Detail) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at Beginning of Period	$228	$471	$339
Additions (Recovery) to Bad Debt Expense or Deferred Tax Asset	11	-128	139
Charged to Other Accounts	'	'	'
Deductions	-33	-115	-7
Balance at End of Period	$206	$228	$471